<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420309995</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.113027</dc:identifier><eid>1-s2.0-S0223523420309995</eid><prism:doi>10.1016/j.ejmech.2020.113027</prism:doi><pii>S0223-5234(20)30999-5</pii><dc:title>Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3 </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>211</prism:volume><prism:startingPage>113027</prism:startingpage><prism:pageRange>113027</prism:pagerange><articleNumber>113027</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-02-05</prism:coverdate><prism:coverDisplayDate>5 February 2021</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Ma, Shumeng</dc:creator><dc:creator>Zhu, Longqing</dc:creator><dc:creator>Fan, Xiaohong</dc:creator><dc:creator>Luo, Tian</dc:creator><dc:creator>Liu, Dan</dc:creator><dc:creator>Liang, Ziyi</dc:creator><dc:creator>Hu, Xiaoling</dc:creator><dc:creator>Shi, Tao</dc:creator><dc:creator>Tan, Wen</dc:creator><dc:creator>Wang, Zhen</dc:creator><dc:description>
                  The combination between two well-studied bioactive compounds melatonin and salicylic acid with proper modifications unexpectedly creates a sharp pair of “scissors” cutting off the vicious connection between inflammation and cancer by targeting a key contributor Signal Transducers and Activators of Transcription 3 (STAT3) in the two pathological processes. A representative compound P-3 with IC50 values on each tested cell line ranging from 7.37 to 18.62 μM among the designed melatonin derivatives is equipped with the ability of curbing inflammation-promoting cancer by down-regulating the expression, activation and nuclear translocation of STAT3, breaking the feedforward loop of STAT3 activation by decreasing the expression of pro-tumorigenic cytokines, and inducing cell apoptosis through ROS triggered Cyto-c/Caspase-3 pathway. This study suggests that the melatonin derivative P-3 is likely to become a promising chemical structure for developing the novel anti-cancer agents taking effect through hindering the mutual-promoting processes between inflammation and cancer.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Melatonin</dcterms:subject><dcterms:subject>N-salicylic acid</dcterms:subject><dcterms:subject>Inflammation-associated cancer</dcterms:subject><dcterms:subject>STAT3</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420309995" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420309995" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="355" size="37617">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="607" size="139475">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="508" height="83" size="10845">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="208" size="62881">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="464" size="65715">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="156" size="31171">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="181" size="24321">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="512" size="209223">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="243" size="36615">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="626" size="186264">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="407" size="90984">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="696" size="118939">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="272" size="18889">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="415" size="77474">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="134" size="5747">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="164" size="12181">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="36" size="2463">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="76" size="12454">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="163" size="7660">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="64" size="4621">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="4540">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="214" height="164" size="26595">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="4807">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="175" height="164" size="16480">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="143" size="11218">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="136" height="163" size="9860">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="153" size="4989">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="9760">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="1571" size="223923">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="2686" size="1189523">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2248" height="366" size="81379">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2666" height="923" size="459557">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="2054" size="496242">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="691" size="258662">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="802" size="191538">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2962" height="2269" size="2475289">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="1076" size="221103">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2962" height="2773" size="1416636">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="1802" size="650689">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="3081" size="1002212">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1722" height="1204" size="134015">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="1838" size="663785">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="38548480">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-mmc1.doc?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="3684067">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309995-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85096859883</scopus-id><scopus-eid>2-s2.0-85096859883</scopus-eid><pubmed-id>33248852</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85096859883" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20201117">2020-11-17</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20201117">2020-11-17</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210122">2021-01-22</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210122">2021-01-22</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-06-21T12:42:48</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420309995</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30999-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420309995</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.113027</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00249</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210621">2021-06-21T12:35:13.492231Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210205</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1605579810">2020-11-17T02:23:30.039938Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid otherkwds primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>211</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>211</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 211</xocs:vol-iss-suppl-text>
      <xocs:sort-order>49</xocs:sort-order>
      <xocs:first-fp>113027</xocs:first-fp>
      <xocs:article-number>113027</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113027</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20210205</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 February 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-02-05</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>MELATONINDERIVATIVESCOMBATINFLAMMATIONRELATEDCANCERBYTARGETINGMAINCULPRITSTAT3</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>MA</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemical synthesis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological studies</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Anti-proliferation activity and SARs</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound P-3 inhibited the proliferation of HCT-116 and MGC-803 cells and arrested the cell cycle of HCT-116 at G<ce:inf loc="post">0</ce:inf>/G<ce:inf loc="post">1</ce:inf> phase</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound P-3 induced cell apoptosis on HCT-116 cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound P-3 weakened the invasion and migration ability of HCT-116 and MGC-803 cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound P-3 down-regulated the expression of pro-tumorigenic cytokines, STAT3, Bcl-2 and inhibited the nuclear translocation of STAT3</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Docking study revealing the possible interaction model between compound P-3 and STAT3</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound P-3 induced HCT-116 cells apoptosis via ROS-triggered Cyto-c/Caspase-3 pathway</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Acute toxicity study of compound P-3 on mice</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pharmacokinetic study of compound P-3 on rats</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experiment</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>HPLC analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>General procedure for the preparation of compounds</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(5-methoxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(phenylamino)benzamide</ce:italic> 
                     <ce:bold>(P-1)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(methyl(phenyl)amino)benzamide</ce:italic> 
                     <ce:bold>(P-2)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((3-chloro-2-methylphenyl)amino)benzamide</ce:italic> 
                     <ce:bold>(P-3)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>2-((3-chloro-2-methylphenyl)amino)-N-(2-(5-methoxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-ben-zamide</ce:italic> 
                     <ce:bold>(P-4)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(methylamino)benzamide</ce:italic> 
                     <ce:bold>(P-5)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(dimethylamino)benzamide</ce:italic> 
                     <ce:bold>(P-6)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((2,3-dimethylphenyl)amino)benzamide</ce:italic> 
                     <ce:bold>(P-7)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>2-((2,3-dimethylphenyl)amino)-N-(2-(5-hydroxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)ben-zamide</ce:italic> 
                     <ce:bold>(P-8)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclopropylamino)benzamide</ce:italic> 
                     <ce:bold>(Q-1)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclopentylamino)benzamide</ce:italic> 
                     <ce:bold>(Q-2)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclohexylamino)benzamide</ce:italic> 
                     <ce:bold>(Q-3)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(benzylamino)benzamide</ce:italic> 
                     <ce:bold>(Q-4)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.13</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((3,4-dimethoxyphenethyl)amino)benzamide</ce:italic> 
                     <ce:bold>(Q-5)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.14</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((4-hydroxybutyl)amino)benzamide</ce:italic> 
                     <ce:bold>(Q-6)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.15</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(4-methylphenylsulfonamido)benzamide</ce:italic> 
                     <ce:bold>(Q-7)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cells culture</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Proliferation evaluation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>EdU incorporation assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Clonogenicity assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell cycle and apoptosis analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Hoechst staining and Giemsa staining assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Transwell assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>ROS generation determination</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.13</xocs:item-toc-label>
               <xocs:item-toc-section-title>Nuclear translocation assay of STAT3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.14</xocs:item-toc-label>
               <xocs:item-toc-section-title>
                  <ce:italic>ELISA of IL-6 and</ce:italic> TNF-α</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.15</xocs:item-toc-label>
               <xocs:item-toc-section-title>Docking assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.16</xocs:item-toc-label>
               <xocs:item-toc-section-title>Acute toxicity study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.17</xocs:item-toc-label>
               <xocs:item-toc-section-title>Pharmacokinetics study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.18</xocs:item-toc-label>
               <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>COUSSENS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>860</xocs:ref-first-fp>
            <xocs:ref-last-lp>867</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MANTOVANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>436</xocs:ref-first-fp>
            <xocs:ref-last-lp>444</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>AGGARWAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>425</xocs:ref-first-fp>
            <xocs:ref-last-lp>430</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>GRIVENNIKOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>883</xocs:ref-first-fp>
            <xocs:ref-last-lp>899</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>DEMARTEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>194</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>89</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>197</xocs:ref-first-fp>
            <xocs:ref-last-lp>208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>GRIVENNIKOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>883</xocs:ref-first-fp>
            <xocs:ref-last-lp>899</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>QUAIL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1423</xocs:ref-first-fp>
            <xocs:ref-last-lp>1437</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>ATRETKHANY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>98</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>53</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>STEVEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>pG7</xocs:ref-first-fp>
            <xocs:ref-last-lp>G17</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>PETER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>25</xocs:ref-first-fp>
            <xocs:ref-last-lp>35</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>LANDSKRON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>WEST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>615</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>REITER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>654</xocs:ref-first-fp>
            <xocs:ref-last-lp>664</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>REITER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>359</xocs:ref-first-fp>
            <xocs:ref-last-lp>384</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BLASK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>113</xocs:ref-first-fp>
            <xocs:ref-last-lp>132</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>CARBAJOPESCADOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-article-number>e57941</xocs:ref-article-number>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>MARTIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2239</xocs:ref-first-fp>
            <xocs:ref-last-lp>2285</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1459</xocs:ref-first-fp>
            <xocs:ref-last-lp>1470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-last-lp>1409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>FAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112217</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>ENGIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>211</xocs:ref-first-fp>
            <xocs:ref-last-lp>216</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>SIMON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-last-lp>38</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>DENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>3089</xocs:ref-first-fp>
            <xocs:ref-last-lp>3092</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>133</xocs:ref-first-fp>
            <xocs:ref-last-lp>139</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>884</xocs:ref-first-fp>
            <xocs:ref-last-lp>888</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>PANDOLFI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>93e106</xocs:ref-article-number>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>KONDURI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>542</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>COLON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>SALIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2415</xocs:ref-first-fp>
            <xocs:ref-last-lp>2420</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>FRIEDL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>362</xocs:ref-first-fp>
            <xocs:ref-last-lp>374</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>BOWMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>53</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>SCHUMACKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>241</xocs:ref-first-fp>
            <xocs:ref-last-lp>252</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>REED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>773</xocs:ref-first-fp>
            <xocs:ref-last-lp>776</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>MAX2021X113027</xocs:refkey3>
         <xocs:refkey4ai>MAX2021X113027XS</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-01-22T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-01-22T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-05-28T08:56:41.363Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Fundamental Research Funds for the Central Universities</xocs:funding-agency-matched-string>
            <xocs:funding-id>lzujbky-2019-ct08</xocs:funding-id>
            <xocs:funding-agency>Fundamental Research Funds for the Central Universities</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100012226</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>1000 Talents Plan</xocs:funding-agency-matched-string>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Recruitment Program of Global Experts</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Recruitment Program of Global Experts</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100010871</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Young Scientists Fund of National Natural Science Fund</xocs:funding-agency-matched-string>
            <xocs:funding-id>81903844</xocs:funding-id>
            <xocs:funding-agency>Young Scientists Fund</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100010909</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>The financial support of this research was provided by the Recruitment Program of Global Experts (1000 Talents Plan) and the Fundamental Research Funds for the Central Universities ( lzujbky-2019-ct08 ), and also supported by the Young Scientists Fund of National Natural Science Fund ( 81903844 ). </xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30999-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420309995</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420309995</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.113027</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-06-21T12:35:13.492231Z</xocs:timestamp>
         <xocs:cover-date-start>2021-02-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/MAIN/application/pdf/823d239243c685237e19d1216d0b5f50/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>5145852</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>16</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420309995-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/PREVIEW/image/png/9c5fa3a1d4ddaea10faea73288f6ed6e/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>61180</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/sc1/DOWNSAMPLED/image/jpeg/1fb06c20b8a3c2f4c6545f98eaa1e153/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37617</xocs:filesize>
               <xocs:pixel-height>355</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr6/DOWNSAMPLED/image/jpeg/225db5fb1e10034061a23ffb8eb01128/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>139475</xocs:filesize>
               <xocs:pixel-height>607</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx2/DOWNSAMPLED/image/jpeg/aee8822303baef3792f71eb69274f7a5/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10845</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>508</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr9/DOWNSAMPLED/image/jpeg/eae2f166dde95eaba1c120b1a7ba6b9c/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>62881</xocs:filesize>
               <xocs:pixel-height>208</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr2/DOWNSAMPLED/image/jpeg/ccca86a4d50530b55913e58cae1da2b4/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>65715</xocs:filesize>
               <xocs:pixel-height>464</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr1/DOWNSAMPLED/image/jpeg/f298d11a072ac283743979ad9403488e/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31171</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx1/DOWNSAMPLED/image/jpeg/d51345956c1ee777455a95ccf85d1476/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24321</xocs:filesize>
               <xocs:pixel-height>181</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr7/DOWNSAMPLED/image/jpeg/3bb42d9a0ff4f45f95cc99f8fcde9f42/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>209223</xocs:filesize>
               <xocs:pixel-height>512</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr3/DOWNSAMPLED/image/jpeg/7289e4ff131ff3d6268a5ef214dc3524/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36615</xocs:filesize>
               <xocs:pixel-height>243</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr4/DOWNSAMPLED/image/jpeg/678601ccc1ba4d5be29ab076868a4cc3/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>186264</xocs:filesize>
               <xocs:pixel-height>626</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr10/DOWNSAMPLED/image/jpeg/c10cb00d9a7eb2585607d167c0c631d1/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90984</xocs:filesize>
               <xocs:pixel-height>407</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr8/DOWNSAMPLED/image/jpeg/18877bce77f03a47aa66be8c62eeee45/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>118939</xocs:filesize>
               <xocs:pixel-height>696</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr11/DOWNSAMPLED/image/jpeg/20ad5b494b563ce166eb2141ef4ff007/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18889</xocs:filesize>
               <xocs:pixel-height>272</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr5/DOWNSAMPLED/image/jpeg/a814910675769c21905b36fa39d0c52c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>77474</xocs:filesize>
               <xocs:pixel-height>415</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/sc1/THUMBNAIL/image/gif/4b455c169a9cd1d3c5748a4dcade51b7/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5747</xocs:filesize>
               <xocs:pixel-height>134</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr6/THUMBNAIL/image/gif/0f4df8c42706084a171439a9d9131779/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12181</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx2/THUMBNAIL/image/gif/bb72c19e4afe161d0e4c2ef92cc43481/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2463</xocs:filesize>
               <xocs:pixel-height>36</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr9/THUMBNAIL/image/gif/65f3f4e7f9ad90e163dd818305f9f655/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12454</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr2/THUMBNAIL/image/gif/7988e299830db8197e1ec4f9cbf56a4e/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7660</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr1/THUMBNAIL/image/gif/2842d46e1ca6ba9f1987db81c00d46a1/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4621</xocs:filesize>
               <xocs:pixel-height>64</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx1/THUMBNAIL/image/gif/ca11f99f984d0873017afd532406877b/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4540</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr7/THUMBNAIL/image/gif/8820cd080c086497aab09a20c9b291f9/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>26595</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr3/THUMBNAIL/image/gif/53bc581236f4e50483ec620c7ce3ddf1/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4807</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr4/THUMBNAIL/image/gif/c272b64ac330d2b0ecf70ea22a78bf24/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16480</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr10/THUMBNAIL/image/gif/142583ef216df7476e79022c5a385bad/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11218</xocs:filesize>
               <xocs:pixel-height>143</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr8/THUMBNAIL/image/gif/582e8fcdc809031ae33baced1e0476cf/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9860</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>136</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr11/THUMBNAIL/image/gif/891d186296a56131627e5dba81e6127b/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4989</xocs:filesize>
               <xocs:pixel-height>153</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr5/THUMBNAIL/image/gif/3823957a80937f3850572f773ef18ceb/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9760</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/sc1/HIGHRES/image/jpeg/7f47ff75e86307bfa756c7111e977c0a/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>223923</xocs:filesize>
               <xocs:pixel-height>1571</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr6/HIGHRES/image/jpeg/b0901790c346d8c9f90de0722216a2d8/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1189523</xocs:filesize>
               <xocs:pixel-height>2686</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx2/HIGHRES/image/jpeg/39e3594cc4630e670b0775f2df6c866c/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>81379</xocs:filesize>
               <xocs:pixel-height>366</xocs:pixel-height>
               <xocs:pixel-width>2248</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr9/HIGHRES/image/jpeg/9d9ce0c0d5e76af4e3cace007e4fb5e4/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>459557</xocs:filesize>
               <xocs:pixel-height>923</xocs:pixel-height>
               <xocs:pixel-width>2666</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr2/HIGHRES/image/jpeg/dcdbe3357864f60a7fdbcce1000f070e/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>496242</xocs:filesize>
               <xocs:pixel-height>2054</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr1/HIGHRES/image/jpeg/9b88eca8e0ef6b581cf866bbca54abcf/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>258662</xocs:filesize>
               <xocs:pixel-height>691</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/fx1/HIGHRES/image/jpeg/1f1a12924c51ab409fccce0cf0ec49aa/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>191538</xocs:filesize>
               <xocs:pixel-height>802</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr7/HIGHRES/image/jpeg/c7b8ac659af870be9e53c80a798355b1/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2475289</xocs:filesize>
               <xocs:pixel-height>2269</xocs:pixel-height>
               <xocs:pixel-width>2962</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr3/HIGHRES/image/jpeg/652accef8ebde85ba9c76db23fe09397/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>221103</xocs:filesize>
               <xocs:pixel-height>1076</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr4/HIGHRES/image/jpeg/3421daa58016e9b904c91e87a41ceb17/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1416636</xocs:filesize>
               <xocs:pixel-height>2773</xocs:pixel-height>
               <xocs:pixel-width>2962</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr10/HIGHRES/image/jpeg/b3103af3cfa252fb3f02bfb8468f9a5c/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>650689</xocs:filesize>
               <xocs:pixel-height>1802</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr8/HIGHRES/image/jpeg/7cc941375813a39682cf2e4d4987bb7c/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1002212</xocs:filesize>
               <xocs:pixel-height>3081</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr11/HIGHRES/image/jpeg/44858ffb4a70e9d292ad68e5f323ee8b/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>134015</xocs:filesize>
               <xocs:pixel-height>1204</xocs:pixel-height>
               <xocs:pixel-width>1722</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/gr5/HIGHRES/image/jpeg/e857901ff28b1e75408eeead027d2364/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>663785</xocs:filesize>
               <xocs:pixel-height>1838</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-mmc1.doc</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309995/mmc1/MAIN/application/msword/0a22db73d26b96440ce99adf38e722d3/mmc1.doc</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.doc</xocs:filename>
               <xocs:extension>doc</xocs:extension>
               <xocs:filesize>38548480</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309995-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:102Q04Z459B/MAIN/application/pdf/8d69265080f85b8157f3ee4c05b2691a/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>3684067</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113027</aid>
            <ce:article-number>113027</ce:article-number>
            <ce:pii>S0223-5234(20)30999-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.113027</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Relationships between inflammation and cancer.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420309995/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Design and modification strategy of target compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420309995/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Effects of compound P-3 on cell viability of HCT-116 and MGC-803 cells. (A) Cell viability of HCT-116 cells exposed to compound P-3 at different concentrations for 24 h or 48 h (B) Cell viability of MGC-803 cells exposed to compound P-3 at different concentrations for 24 h or 48 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420309995/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Effect of compound P-3 on the proliferation of HCT-116 and MGC-803 cells. (A). Effect of compound P-3 on clonogenicity of HCT-116 cells at different concentrations after 9-days treatment. (B). Effect of compound P-3 on clonogenicity of MGC-803 cells at different concentrations after 6-days treatment. (C) EdU proliferation assay of HCT-116 cells (magnification 20×, scale bar = 100 μm) treated with compound P-3 at different concentrations for 24 h. (D) EdU proliferation assay of MGC-803 cells (magnification 10×, scale bar = 200 μm) treated with compound P-3 at different concentrations for 24 h. Data are presented as mean ± SD from three independent experiments. ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420309995/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">(A) Cell cycle distribution of HCT-116 cells treated with compound P-3 at different concentrations for 48 h and the quantitative analysis of the cell cycle distribution at each phase. Data are presented as mean ± SD from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420309995/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Apoptosis analysis of HCT-116 cells induced by compound P-3. (A) Percentage of apoptotic HCT-116 cells treated with compound P-3 at different concentrations for 48 h detected by flow cytometry. (B) Percentages of apoptotic HCT-116 cells treated with P-3 at different concentrations for 48 h visualized by Hoechst 33342 staining (magnification 20×, scale bar = 100 μm). The cell nuclei of apoptotic HCT-116 cells in Hoechst staining assay were stained by light blue fluorescence. (C) Apopotic morphological changes of HCT-116 cells induced by the treatment of compound P-3 at different concentrations for 48 h (magnification 40×, scale bar = 100 μm). Red arrow denotes apoptotic cells characterized by cell shrinkage, condensed chromatin, apoptotic body formation and cytoskeleton disintegration. Data are presented as mean ± SD from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420309995/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Effect of compound P-3 on the metastasis of HCT-116 and MGC-803 cells. (A) Inhibitory effect on the invasion and migration ability of HCT-116 cells treated with compound P-3 at different concentrations for 36 h (magnification 10×, scale bar = 100 μm) (B) Inhibitory effect on invasion and migration ability of MGC-803 cells treated with compound P-3 at different concentrations for 24 h (magnification 10× and scale bar = 200 μm for invasion; magnification 20× and scale bar = 100 μm for migration). Data are presented as mean ± SD from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420309995/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">(A) Compound P-3 down-regulated the levels of IL-6 and TNF-α in RAW 264.7. The cell viability of RAW 264.7 is higher than 80% under the treatment of compound P-3 at indicated concentrations. (B) Compound P-3 suppressed the expression of STAT3, phosphorylated STAT3, and Bcl-2 in both HCT-116 and MGC-803 cells. (C) Compound P-3 inhibited the nuclear translocation and the total amount of STAT3 in both HCT-116 and MGC-803 cells. Data are presented as mean ± SD from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523420309995/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">3D diagram of compound P-3 inserting into the SH2 domain of STAT3. (A) Residues in the active site were displayed in line style. Compound P-3 was represented with sticks (turquoise). The dash lines showed the potential hydrogen bond (yellow), p-π conjugated bond (green) with bond length indicated by purple numbers. (B) 3D structure of the protein was presented in surface and several residues were displayed. P-3 was represented with sticks (Pink). Arrows denoted potential binding sub-pockets accessed by P-3. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523420309995/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">(A) Compound P-3 triggered the explosion of ROS in HCT-116 cells. (magnification 20×, scale bar = 100 μm) (B) P-3 regulated the expression of proteins involved in Cyto-c/Caspase3 pathway. Data are presented as mean ± SD from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523420309995/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Pharmacokinetic curve of compound P-3 obtained from serum samples of five SD rats subjected to intragastric administration of compound P-3 at the dosage of 100 mg/kg. Data for compound P-3 was shown as the mean ± SD, n = 5.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523420309995/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Synthesis of melatonin derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420309995/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0010" view="all">Anti-proliferation activity of compounds on different cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Table 1</ce:alt-text>
               <tgroup cols="9">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Comp.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col9" namest="col2" role="colgroup">IC<inf loc="post">50</inf> ± SD<cross-ref id="crosref0400" refid="tbl1fna">
                              <sup loc="post">a</sup>
                           </cross-ref> (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HePG-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MGC-803</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SGC-7901</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HGC-27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AGS</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.67 ± 1.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.04 ± 1.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.75 ± 1.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.23 ± 0.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.57 ± 0.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.27 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.06 ± 1.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.7 ± 1.98</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.42 ± 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.82 ± 0.56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.37 ± 0.90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.62 ± 1.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.96 ± 0.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.46 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.49 ± 1.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.12 ± 0.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.40 ± 0.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.26 ± 3.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.93 ± 0.98</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.78 ± 0.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.80 ± 0.57</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.95 ± 0.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.93 ± 2.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.02 ± 1.19</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.60 ± 3.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.55 ± 0.98</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.42 ± 2.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.69 ± 1.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.60 ± 1.97</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.24 ± 0.96</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.28 ± 0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.96 ± 0.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.46 ± 0.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.96 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.97 ± 0.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.43 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.28 ± 1.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.75 ± 1.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.26 ± 4.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.60 ± 1.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.74 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.93 ± 0.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Q-7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>5-FU</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.10 ± 2.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.16 ± 2.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.15 ± 2.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.04 ± 1.44</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Melatonin</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>30</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">MTT method; cells were treated with compounds at different concentrations for 72 h; the data were mean ± SD (n = 3).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0015" view="all">Pharmacokinetic parameters of compound P-3 obtained from serum samples of five SD rats subjected to intragastric administration of compound P-3 at the dosage of 100 mg/kg.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Table 2</ce:alt-text>
               <tgroup cols="9">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col2" namest="col1" role="colgroup">Parameter<cross-ref id="crosref0405" refid="tbl2fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">t<inf loc="post">1/2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">T<inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">C<inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-t</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-inf_obs</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-t/o-inf_obs</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cl/F<inf loc="post">_obs</inf>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>P-3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col3" namest="col2" role="colgroup">7.58</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.1495</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">51.75</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Unit</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col3" namest="col2" role="colgroup">h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">μg/mL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">μg/mL∗h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">μg/mL∗h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(mg/kg)/(μg/mL)/h</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">The analyzing method was Linear Trapezoidal in a non-compartmental model using the PKsolver2.0 computer program.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:title id="title0010">Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420309995-c87d0bd3b34d94d3ff8b02c8ff178efa">
                  <ce:given-name>Shumeng</ce:given-name>
                  <ce:surname>Ma</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420309995-5b0abca0103a1daa13757e36c5c489d1">
                  <ce:given-name>Longqing</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420309995-454b84fecb6fe71ba3bf4294f5869594">
                  <ce:given-name>Xiaohong</ce:given-name>
                  <ce:surname>Fan</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420309995-0227ff56064f7524fa7639c6c93962b9">
                  <ce:given-name>Tian</ce:given-name>
                  <ce:surname>Luo</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420309995-b5147701866b90aca99fb1d64f5dc909">
                  <ce:given-name>Dan</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420309995-7d0b0acda45b958de92f148db38aa26d">
                  <ce:given-name>Ziyi</ce:given-name>
                  <ce:surname>Liang</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420309995-8554170a1dc644b18bb85eaa0d8a4749">
                  <ce:given-name>Xiaoling</ce:given-name>
                  <ce:surname>Hu</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420309995-383d333bd8300b661b830d2d3c1f579e">
                  <ce:given-name>Tao</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="cor3">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au9" author-id="S0223523420309995-8457044177cf5522aed5737c3ceb33a1">
                  <ce:given-name>Wen</ce:given-name>
                  <ce:surname>Tan</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" orcid="0000-0003-4134-1779" author-id="S0223523420309995-d7b4725b7fb6a09ec1f4a957e6a32fca">
                  <ce:given-name>Zhen</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0080" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0085" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420309995-71434b8afaee7bd00cca9f9f134b5d90">
                  <ce:label>a</ce:label>
                  <ce:textfn>School of Pharmacy, Lanzhou University, Lanzhou, 730000, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Lanzhou University</sa:organization>
                     <sa:city>Lanzhou</sa:city>
                     <sa:postal-code>730000</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">School of Pharmacy, Lanzhou University, Lanzhou, 730000, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420309995-cbfcfa5a7094cf43cfd2520fb6087bf7">
                  <ce:label>b</ce:label>
                  <ce:textfn>State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>State Key Laboratory of Applied Organic Chemistry</sa:organization>
                     <sa:organization>College of Chemistry and Chemical Engineering</sa:organization>
                     <sa:organization>Lanzhou University</sa:organization>
                     <sa:city>Lanzhou</sa:city>
                     <sa:postal-code>730000</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. School of Pharmacy, Lanzhou University, Lanzhou, 730000, China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Lanzhou University</sa:organization>
                     <sa:city>Lanzhou</sa:city>
                     <sa:postal-code>730000</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors made equal contributions to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="24" month="8" year="2020"/></ce:date-received>
            <ce:date-revised day="22" month="10" year="2020"/></ce:date-revised>
            <ce:date-accepted day="12" month="11" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">The combination between two well-studied bioactive compounds melatonin and salicylic acid with proper modifications unexpectedly creates a sharp pair of “scissors” cutting off the vicious connection between inflammation and cancer by targeting a key contributor Signal Transducers and Activators of Transcription 3 (STAT3) in the two pathological processes. A representative compound P-3 with IC<ce:inf loc="post">50</ce:inf> values on each tested cell line ranging from 7.37 to 18.62 μM among the designed melatonin derivatives is equipped with the ability of curbing inflammation-promoting cancer by down-regulating the expression, activation and nuclear translocation of STAT3, breaking the feedforward loop of STAT3 activation by decreasing the expression of pro-tumorigenic cytokines, and inducing cell apoptosis through ROS triggered Cyto-c/Caspase-3 pathway. This study suggests that the melatonin derivative P-3 is likely to become a promising chemical structure for developing the novel anti-cancer agents taking effect through hindering the mutual-promoting processes between inflammation and cancer.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420309995/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Melatonin</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>N-salicylic acid</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Inflammation-associated cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords class="abr" id="kwrds0015" xml:lang="en" view="all">
               <ce:section-title id="sectitle0030">Abbreviations</ce:section-title>
               <ce:keyword id="kwrd0030">
                  <ce:text>IC<ce:inf loc="post">50</ce:inf>
                  </ce:text>
                  <ce:keyword id="kwrd0035">
                     <ce:text>Half-maximum inhibitory concentration</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0040">
                  <ce:text>LD<ce:inf loc="post">50</ce:inf>
                  </ce:text>
                  <ce:keyword id="kwrd0045">
                     <ce:text>Dose that is lethal in 50% of test subjects</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0050">
                  <ce:text>SD</ce:text>
                  <ce:keyword id="kwrd0055">
                     <ce:text>Standard deviation</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0060">
                  <ce:text>LPS</ce:text>
                  <ce:keyword id="kwrd0065">
                     <ce:text>Lipopolysaccharide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0070">
                  <ce:text>PBS</ce:text>
                  <ce:keyword id="kwrd0075">
                     <ce:text>Phosphate-buffered saline</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0080">
                  <ce:text>TNF-α</ce:text>
                  <ce:keyword id="kwrd0085">
                     <ce:text>Tumor necrosis factor-alpha</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0090">
                  <ce:text>IL-6</ce:text>
                  <ce:keyword id="kwrd0095">
                     <ce:text>Interleukin-6</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0100">
                  <ce:text>IL-10</ce:text>
                  <ce:keyword id="kwrd0105">
                     <ce:text>Interleukin-10</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0110">
                  <ce:text>ROS</ce:text>
                  <ce:keyword id="kwrd0115">
                     <ce:text>Reactive oxygen species</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0120">
                  <ce:text>DCFH-DA</ce:text>
                  <ce:keyword id="kwrd0125">
                     <ce:text>2,7-dichlorodi-hydrofluorescein</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0130">
                  <ce:text>DMSO</ce:text>
                  <ce:keyword id="kwrd0135">
                     <ce:text>Dimethyl sulphoxide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0140">
                  <ce:text>FBS</ce:text>
                  <ce:keyword id="kwrd0145">
                     <ce:text>Fetal bovine serum</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0150">
                  <ce:text>STAT3</ce:text>
                  <ce:keyword id="kwrd0155">
                     <ce:text>Signal Transducers and Activators of Transcription 3</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">In human body as an organic whole, any pathological process can hardly be regarded as an isolated event. In the past few decades, an increasing number of evidences revealed the intricate and intertwined relationships between inflammation and cancer [<ce:cross-refs id="crosrefs0010" refid="bib1 bib2 bib3 bib4">1–4</ce:cross-refs>]. Chronic inflammation induced by external factors such as bacterial infection [<ce:cross-ref id="crosref0095" refid="bib5">5</ce:cross-ref>], smoking [<ce:cross-ref id="crosref0100" refid="bib6">6</ce:cross-ref>], and high calorie diet [<ce:cross-ref id="crosref0105" refid="bib7">7</ce:cross-ref>], are likely to contribute to gene instability or damage as well as proto-oncogene mutation, further leading to tumorigenesis. It can also accelerate tumor development by provoking immunosuppression and impairing anti-cancer immunity [<ce:cross-ref id="crosref0110" refid="bib5">5</ce:cross-ref>]. After tumor initiation, the necrosis of cancer cells caused by a scarcity of blood supply or microbism as the result of barrier deterioration may also elicit inflammation [<ce:cross-ref id="crosref0115" refid="bib8">8</ce:cross-ref>]. Such concomitant inflammation contributes to the formation of tumor microenvironment constituted by diverse immune cells, cancer cells and cytokines and chemokines they produced, which in turn drives the progression of malignancy in most solid tumor [<ce:cross-ref id="crosref0120" refid="bib8">8</ce:cross-ref>,<ce:cross-ref id="crosref0125" refid="bib9">9</ce:cross-ref>]. Cancer cells may further amplify the tumor microenvironment by recruiting more immune cells with chemokines, aggravating and maintaining the inflammatory state [<ce:cross-ref id="crosref0130" refid="bib10">10</ce:cross-ref>]. Consequently, a chronic feedforward loop of tumorigenesis and metastasis is established [<ce:cross-ref id="crosref0135" refid="bib11">11</ce:cross-ref>] (<ce:cross-ref id="crosref0140" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0030" view="all">A linchpin between the chronic inflammation and cancer is the Signal Transducers and Activators of Transcription 3 (STAT3). STAT3 as a nuclear transcription factor persistently being activated in cancer cells and inflammatory cells in tumor microenvironment is responsible for transducing cytoplasmic signals of extracellular stimuli and regulating genes involved in tumor proliferation, survival, angiogenesis, invasion and additionally genes of cancer-promoting inflammatory mediators [<ce:cross-refs id="crosrefs0015" refid="bib13 bib14">12,13</ce:cross-refs>]. The activation of STAT3 and its subsequent consequences have been well-studied in many classic inflammation-dependent cancers such as colorectal cancer and gastric cancer [<ce:cross-refs id="crosrefs0020" refid="bib15 bib16 bib17 bib18">14–17</ce:cross-refs>]. It has been demonstrated that during the process of chronic gastrointestinal inflammation, the chance of tumorigenesis largely ascends due to the activation of STAT3 as well as the production of pro-tumorigenic cytokines interleukin-6 (IL-6), tumor necrosis factor (TNF-α), etc. [<ce:cross-ref id="crosref0145" refid="bib17">16</ce:cross-ref>,<ce:cross-ref id="crosref0150" refid="bib18">17</ce:cross-ref>]. Therefore, impeding the mutual-promoting processes between chronic inflammation and cancer by suppressing the biological functions of STAT3 or the expression of pro-tumorigenic cytokines in tumor microenvironment would be a promising strategy to combat inflammation-related colorectal and gastric carcinoma [<ce:cross-ref id="crosref0160" refid="bib20">18</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">Melatonin as a well-known hormone produced by pineal gland has diverse physiological functions including affecting circadian rhythms [<ce:cross-ref id="crosref0165" refid="bib21">19</ce:cross-ref>], changing cellular redox status [<ce:cross-ref id="crosref0170" refid="bib22">20</ce:cross-ref>], and anti-tumor [<ce:cross-ref id="crosref0175" refid="bib23">21</ce:cross-ref>]. Notably, it has been reported that melatonin exerts its multiple bioactivities, especially its anti-tumor effect, partially via STAT3 pathway [<ce:cross-refs id="crosrefs0025" refid="bib24 bib25 bib26 bib27">22–25</ce:cross-refs>]. Another “old friend” salicylic acid, which is famous for its derivative acetylsalicylic acid, a classical anti-inflammation agent also known as Aspirin, once again amazed us with its novel derivatives represented by S3I-201.1066 entitled with great anti-cancer activity by inhibiting STAT3 aberrant activation and functions in human cancer cells [<ce:cross-refs id="crosrefs0030" refid="bib28 bib29 bib30">26–28</ce:cross-refs>]. In our previous research, the designed compounds following the combination strategy between melatonin and N-salicyloyl derivatives had been proven possessing satisfying anti-neuroinflammatory activity by inhibiting cyclooxygenase (COX), scavenging radicals, and inhibiting activation of glial cells [<ce:cross-ref id="crosref0180" refid="bib31">29</ce:cross-ref>] (<ce:cross-ref id="crosref0185" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>). The modification also granted a lower acidity to these compounds compared to the majority of non-steroidal anti-inflammatory drugs (NSAIDs) by shielding the acid groups. In consideration of a “reversed” pH gradient (intracellular pH is higher than the extracellular pH) in most cancer cells compared to normal cells [<ce:cross-ref id="crosref0190" refid="bib32">30</ce:cross-ref>], and most anticancer drugs are ionizable, an appropriate pK<ce:inf loc="post">a</ce:inf> trait of anti-cancer drugs, which determines the portion of drugs in a neutral form (accessible to cancer focus and permeable into cancer cytomembrane), could enhance the drugs’ efficiency [<ce:cross-ref id="crosref0195" refid="bib33">31</ce:cross-ref>]. Enlightened by the studies above, a series of modifications had been done on the structure of melatonin and N-salicylic acid following the similar modification strategy with the aim of making a combination of anti-cancer and anti-inflammation properties from the two fragments (<ce:cross-ref id="crosref0200" refid="sch1">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0040" view="all">In short, based on firstly the potential anti-tumor and anti-inflammation activity of melatonin N-salicyloyl derivatives, secondly the proper acidity of these compounds compared to classic NSAIDs and thirdly the close connection between inflammation and cancer, the anti-tumor effect of these compounds on inflammation-dependent cancers, especially on coloectal and gastric carcinoma, was explored and a brief structure and activity relationship (SAR) was concluded. Subsequently, the primary anti-tumor mechanisms of the representative compound P-3 were studied and rationalized by docking assay. In addition, the toxicity and pharmacokinetic profile of compound P-3 were evaluated, which may provide a guidance for further structure optimization and hit-to-lead transformation. More significantly, this research may provide us with an approach of thinking out of the box to discover novel “anti-inflammatory anti-tumor agents”.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Chemical synthesis</ce:section-title>
                     <ce:para id="p0045" view="all">The derivatives of melatonin were synthesized by employing a well-established methodology displayed as follows [<ce:cross-ref id="crosref0205" refid="bib31">29</ce:cross-ref>] (<ce:cross-ref id="crosref0210" refid="sch1">Scheme 1</ce:cross-ref>). To be specific, a condensation reaction was happened between N-salicylic acid derivatives and melatonin derivatives under the presence of EDCI, HOBt and triethylamine. All compounds were identified by NMR and mass spectrometry with 70%–90% overall yields and purity no less than 95.0% monitored by HPLC.</ce:para>
                     <ce:para id="p0050" view="all">Compounds P-1 [<ce:cross-ref id="crosref0215" refid="bib34">32</ce:cross-ref>], P-2 [<ce:cross-ref id="crosref0220" refid="bib31">29</ce:cross-ref>], P-3 [<ce:cross-ref id="crosref0225" refid="bib34">32</ce:cross-ref>], P-4 [<ce:cross-ref id="crosref0230" refid="bib31">29</ce:cross-ref>], P-5 [<ce:cross-ref id="crosref0235" refid="bib35">33</ce:cross-ref>], P-6 [<ce:cross-ref id="crosref0240" refid="bib36">34</ce:cross-ref>], P-7 [<ce:cross-ref id="crosref0245" refid="bib37">35</ce:cross-ref>], P-8 [<ce:cross-ref id="crosref0250" refid="bib31">29</ce:cross-ref>] have been reported previously, while compounds Q-1 to Q-7 have not been reported.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0050">Biological studies</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0055">Anti-proliferation activity and SARs</ce:section-title>
                        <ce:para id="p0055" view="all">The anti-proliferation activity of compounds P-1 to P-8 and Q-1 to Q-7 were evaluated on several inflammation-related cancer cell lines, which were gastric cancer cell lines (MGC-803, SGC-7901, HGC-27, AGS), colon cancer cell line (HCT-116), breast cancer cell line (MCF-7), hepatoma carcinoma cell line (HepG2), and lung cancer cell line (A549) using MTT assay with 5-FU as a positive control, and melatonin as a reference. The results indicated that most compounds showed improved anti-proliferation activity towards tested cancer cell lines compared to the parent compound melatonin especially on colon and gastric cancer cells (<ce:cross-ref id="crosref0255" refid="tbl1">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor>). Besides, the structure activity relationships (SARs) of the compounds with different substituent groups on the nitrogen of N-salicylic acid fragment were that firstly compounds with aliphatic substituents no matter a chain or a ring had a narrow anti-tumor spectrum than those substituted by an aromatic ring; secondly, regarding the number of carbon atoms between aromatic ring and the nitrogen atom, naught was better than one or two carbon atoms; thirdly, for those whose substituents on aromatic ring with diverse electronic effects, a substituent with electron-withdrawing effect in meta position (compound P-3) was better than a donating one (compound P-7). Notably, compound P-3 exhibited the best anti-proliferation activity in general towards the tested cell lines possibly because the fragment connected to melatonin-like fragment is a tolfenamic acid, which has also been reported with anti-tumor activity [<ce:cross-ref id="crosref0260" refid="bib38">36</ce:cross-ref>,<ce:cross-ref id="crosref0265" refid="bib39">37</ce:cross-ref>]. However, retaining the methoxy group of melatonin (compound P-4) showed weaker anti-proliferation activity than removing it (compound P-3). Thus, compound P-3 was selected for further anti-cancer study on colon cancer cells HCT-116 and gastric cancer cells MGC-803.</ce:para>
                        <ce:para id="p0060" view="all">To determine the appropriate dose of compound P-3 in subsequent assays, CCK8 test was employed to collect comparatively accurate cell viability of HCT-116 and MGC-803 cells treated by compound P-3 at different concentrations for 24 h and 48 h. In the 24 h viability study (indicated by orange lines in <ce:cross-ref id="crosref0270" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>), the HCT-116 cells had high viability (cell viability no less than 80%) at low compound P-3 concentration until the concentration was above 36 μM, whereas MGC-803 cell could maintain high viability only when the concentration was less than 20 μM. When exposed to compound P-3 for 48 h (indicated by blue lines in <ce:cross-ref id="crosref0275" refid="fig3">Fig. 3</ce:cross-ref>), the tested concentrations less or around 20 μM and 10 μM could keep HCT-116 cells and MGC-803 cells respectively in a high viability state.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0060">Compound P-3 inhibited the proliferation of HCT-116 and MGC-803 cells and arrested the cell cycle of HCT-116 at G<ce:inf loc="post">0</ce:inf>/G<ce:inf loc="post">1</ce:inf> phase</ce:section-title>
                        <ce:para id="p0065" view="all">Human tumor Clonogenic Assays (HTCA) is a common method utilized to predict the anti-proliferation activity of drugs in <ce:italic>in vitro</ce:italic> drug screening. Within a short time period, a single cancer cell could rapidly proliferate to form a colony of daughter cells, which is large enough to be observed with bare eyes after being stained by crystal violet dye. Thus, the proliferation ability of cancer cells can be evaluated by counting the number of colonies larger than a specific threshold. The outcomes showed that compound P-3 exerted inhibitory effects on the clonogenicity process of both HCT-116 and MGC-803 cells in a concentration-dependent manner (<ce:cross-ref id="crosref0280" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>A and B).</ce:para>
                        <ce:para id="p0070" view="all">EdU(5-ethynyl-2′-deoxyuridine), a terminal alkyne-containing nucleoside analog, can incorporate into DNA during the progress of DNA synthesis due to its similarity to thymidine. The alkyne of EdU can react with an azide-containing fluorochrome in a Cu (I)-catalyzed reaction, forming a stable covalent bond. The detection of fluorescent signals of incorporated EdU in DNA provides the information on cell proliferation and the proportion of cells in S-phase [<ce:cross-ref id="crosref0285" refid="bib40">38</ce:cross-ref>]. The results indicated that compound P-3 could decrease the percentage of cells at S-phase, which indicated its inhibitory effect on cell proliferation of HCT-116 (<ce:cross-ref id="crosref0290" refid="fig4">Fig. 4</ce:cross-ref>C) and MGC-803 (<ce:cross-ref id="crosref0295" refid="fig4">Fig. 4</ce:cross-ref>D).</ce:para>
                        <ce:para id="p0075" view="all">Next, HCT-116 and MGC-803 cells treated with compound P-3 were subjected to cell cycle assay via flow cytometry (FCM) based on propidium iodide (PI) staining method. As depicted in <ce:cross-ref id="crosref0300" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>A, the cell cycle of HCT-116 cells was arrested at G<ce:inf loc="post">0</ce:inf>/G<ce:inf loc="post">1</ce:inf> phase by compound P-3 with the portion of this phase growing from 70.45% to 84.74% as concentrations of P-3 rose from 0 to 20 μM. Nevertheless, no obvious effect on cell cycle was detected on MGC-803 cells as can be seen in the Supporting <ce:bold>Information</ce:bold>.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0065">Compound P-3 induced cell apoptosis on HCT-116 cells</ce:section-title>
                        <ce:para id="p0080" view="all">To determine the apoptosis-inducing effect of compound P-3, firstly flow cytometry (FCM) was applied with two fluorescent dyes PI and Annexin-V. A concentration-dependent (2.5 μM, 5 μM, 10 μM, 20 μM) increase (from 2.14% to 42.50%) appeared on the portion of early stage apoptosis of HCT-116 (<ce:cross-ref id="crosref0305" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>A). In comparison, the apoptosis-inducing effect on MGC-803 cells was quite weak (Supporting <ce:bold>Information</ce:bold>), which means the cytotoxicity effect of compound P-3 on MGC-803 cells might not exert by inducing apoptosis only.</ce:para>
                        <ce:para id="p0085" view="all">Afterwards, Hoechst staining and Giemsa staining assays were performed on HCT-116 cells by treating the cells with compound P-3 at different concentrations (1.25 μM, 2.5 μM, 5 μM, 10 μM and 2.5 μM, 5 μM, 10 μM, 15 μM respectively). The Hoechst staining assay further verified that compound P-3 was able to induce the apoptosis of HCT-116 cells indicated by the increased percentage of apoptotic cells with twinkling cell nuclei stained by Hoechst 33342 (<ce:cross-ref id="crosref0310" refid="fig6">Fig. 6</ce:cross-ref>B). Consistently, HCT-116 cells in Giemas staining assay showed that HCT-116 cells appeared classic morphological changes of apoptosis such as apoptosis body formation, chromatin pyknosis and plasmatorrhexis compared to the control group, in which the chromatin distributed evenly in cell nuclei and the cytomembranes were integrated (<ce:cross-ref id="crosref0315" refid="fig6">Fig. 6</ce:cross-ref>C).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0070">Compound P-3 weakened the invasion and migration ability of HCT-116 and MGC-803 cells</ce:section-title>
                        <ce:para id="p0090" view="all">As cancer cells undergo metastasis (invasion and migration of a new tissue), they penetrate and attach to the basal matrix of target tissue, allowing the cancer cells to form a focus in deep tissues or transfer to another tissues to form a new tumor focuses, which is a crucial trick played by most cancer cells against cancer therapies [<ce:cross-ref id="crosref0320" refid="bib41">39</ce:cross-ref>]. In order to test the effect of compound P-3 on the invasion and migration of cancer cells, transwell chambers were used. Seduced by high FBS-containing medium in the lower chambers, the vast majority of serum-starved HCT-116 cells and MGC-803 cells moved towards the lower chamber through polycarbonate membrane in the migration assay or through polycarbonate membrane covered with matrigel in the invasion assay. In comparison, after being treated with compound P-3, both cell lines demonstrated an impaired mobility in two assays in a concentration-dependent manner as shown in <ce:cross-ref id="crosref0325" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>A and <ce:cross-ref id="crosref0330" refid="fig7">Fig. 7</ce:cross-ref>B.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>
                           <ce:bold>2.2.5</ce:bold>
                        </ce:label>
                        <ce:section-title id="sectitle0075">Compound P-3 down-regulated the expression of pro-tumorigenic cytokines, STAT3, Bcl-2 and inhibited the nuclear translocation of STAT3</ce:section-title>
                        <ce:para id="p0095" view="all">
                           <ce:bold>I</ce:bold>n tumor microenvironment, various pro-inflammatory cytokines such as IL-6, IL-10, IL-21, IL-23, produced by immune cells can bind to and activate the cell surface receptors, recruiting members of the Janus kinase (JAK) family to act as intermediaries for activation of STAT3. JAK-mediated phosphorylation of an invariant tyrosine residue on the receptor-bound STAT3 monomer induces the phosphorylated STAT3 (p-STAT3) monomers to associate with each other. The activated dimers then translocate into the nucleus and bind to specific DNA-response elements in the promoters of target genes and thereby regulate the expression of certain genes such as IL-6, IL-17, B-cell lymphoma-x (Bcl-x), B-cell lymphoma-2 (Bcl-2), and vascular endothelial growth factor (VEGF), which are related to tumor proliferation, survival, angiogenesis, and invasion [<ce:cross-ref id="crosref0335" refid="bib42">40</ce:cross-ref>]. In this process, IL-6 as both the activator and the targeted gene of STAT3 contributes to the form of a feedforward loop of STAT3 activation in tumor-elicited inflammation [<ce:cross-ref id="crosref0340" refid="bib43">41</ce:cross-ref>]. In addition, TNF-α is also an important pro-tumorigenic inflammatory cytokine that have been shown participating in both the initiation and progression of cancer [<ce:cross-ref id="crosref0345" refid="bib17">16</ce:cross-ref>]. Taking the significant role of IL-6 and TNF-α in tumor-elicited inflammation into consideration, the effect of compound P-3 on the two cytokines was evaluated with ELISA kits. After treated with compound P-3 for 24 h at the concentrations of 5, 10, 15 and 20 μM, the cell supernatant of mouse mononuclear macrophage RAW 264.7 was collected for ELISA. According to the result, compound P-3 decreased the release of IL-6 and TNF-α in RAW 264.7 cells in a concentration-dependent manner (<ce:cross-ref id="crosref0350" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>A), which might mitigate the overactivation of STAT3 and hinder the process of tumorgenesis.</ce:para>
                        <ce:para id="p0100" view="all">To further study the direct influence of compound P-3 on STAT3, western blot assay was performed, which displayed an obvious decrease on the expression of STAT3, phosphorylated STAT3 and STAT3 regulated gene Bcl-2 in compound P-3 treated MGC-803 cells and HCT-116 cells (<ce:cross-ref id="crosref0355" refid="fig8">Fig. 8</ce:cross-ref>B). In addition, nuclear translocation of STAT3 is an indispensable process in order to regulate the expression of tumorgenesis-related genes. Therefore, the effect of compound P-3 on the nuclear translocation of STAT3 was detected by Hoechst dye and fluorochrome-conjugated antibody. From the pictures of HCT-116 and MGC-803 cells exposed to compound P-3 for 3 h, an obvious inhibitory effect on the nuclear translocation of STAT3 was observed in both cell lines. Moreover, in consistent with western blot assay, a decline in gross amount of STAT3 in compound P-3 treated group was also observed from the comparatively sparse STAT3 indicated by red fluorescence compared to the control group (<ce:cross-ref id="crosref0360" refid="fig8">Fig. 8</ce:cross-ref>C).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0080">Docking study revealing the possible interaction model between compound P-3 and STAT3</ce:section-title>
                        <ce:para id="p0105" view="all">To predict the interaction model between compound P-3 and STAT3 in Src Homology 2 (SH2) domain, which plays an essential role in the process of STAT3 phosphorylation and following dimerization, a docking study was carried out based on the crystal structure of STAT3 homo dimer (PDB code: <ce:inter-ref id="intref0010" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>). As can be seen in <ce:cross-ref id="crosref0365" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>, bending from the linker amide bond, the melatonin-like part could reach to a hydrophilic sub-pocket of the SH2 domain (composed of ARG609, SER61l, SER613 and LYS591), while the other tolfenamic acid part could access to a relative hydrophobic sub-pocket (woven by ILE597, ILE634, LYS592, ARG595). In this process, two kinds of interaction forces played important roles, which were hydrogen bond interaction and p-π interaction. To be specific, amide carbonyl formed one strong hydrogen bond (2.45 Å) between the CO and LYS591 and the other strong hydrogen bond (2.27 Å) between the NH and SER636, locating the center of P-3 in between the two adjacent sub-pockets. Further, a p-π interaction (3.52 Å) between the indole ring of the melatonin-like part and LYS591 contributed to the binding process. In general, the amide bond between melatonin-like part and salicylic derivatives is crucial for anchoring the compound into the pocket of SH2 domain and all these interactions rationalized the inhibitory effect of the compound P-3 on STAT3.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0085">Compound P-3 induced HCT-116 cells apoptosis via ROS-triggered Cyto-c/Caspase-3 pathway</ce:section-title>
                        <ce:para id="p0110" view="all">Reactive oxygen species (ROS) is a double-edged sword to cancer cells. In lower content, it functions as signal molecules driving the proliferation and other events required for tumor progression. That is the reason why transformed cells appear to generate more ROS than do normal cells. Nevertheless, evidence also showed that diverse cancer chemotherapeutic agents may be selectively toxic to tumor cells by augmenting oxidant stress and pushing these already stressed cells beyond their limit [<ce:cross-ref id="crosref0370" refid="bib44">42</ce:cross-ref>]. Hence, triggering ROS explosion could be a valuable strategy to initiate the apoptosis of cancer cells. Marked by fluorescent probe DCFH-DA, the cells undergoing ROS explosion can be observed under microscope. The results indicated that the degree and extent of ROS explosion drastically increased with the rise of the dosage of compound P-3 in HCT-116 cells as displayed in <ce:cross-ref id="crosref0375" refid="fig10">Fig. 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor>A.</ce:para>
                        <ce:para id="p0115" view="all">Bcl-2 residues in the permeability transition pore (PT pore) of mitochondria while Bcl-2-associated X (Bax) scatters at the mitochondria matrix. When mitochondria subjected to stimuli, such as overwhelming ROS, Bax could promote the opening of PT pore, allowing cytochrome <ce:italic>c</ce:italic>, an apoptosis signal transducer, to release from the mitochondria into cytoplasm to activate the caspase cascade, inducing cell apoptosis. On the contrary, Bcl-2 could impede the opening of PT pore to antagonize the apoptosis effect of Bax [<ce:cross-ref id="crosref0380" refid="bib45">43</ce:cross-ref>]. Western blot assay revealed that compound P-3 was capable of down-regulating the expression of Bcl-2, Cyto-c and cleaved caspase-3 and up-regulated the expression of Bax (<ce:cross-ref id="crosref0385" refid="fig10">Fig. 10</ce:cross-ref>B). Based on all the findings above, another anti-tumor mechanism of compound P-3 on HCT-116 cells could be through ROS triggered Cyto-c/Caspase-3 pathway.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.8" view="all">
                        <ce:label>2.2.8</ce:label>
                        <ce:section-title id="sectitle0090">Acute toxicity study of compound P-3 on mice</ce:section-title>
                        <ce:para id="p0120" view="all">Acute toxicity evaluation was performed with compound P-3 on three female and three male Kunming mice weighing form 19–22 g. Compound P-3 at the dose of 1000 mg/kg was given by intragastric administration in consideration of the focused gastrointestinal tumor in this study. In the following 14 days, all the mice survived and in a good condition that the hairs, feeding frequency and amount, activity were as normal. Therefore, compound P-3 can be regarded as a comparatively safe compound with oral LD<ce:inf loc="post">50</ce:inf> value higher than 1000 mg/kg.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.9" view="all">
                        <ce:label>2.2.9</ce:label>
                        <ce:section-title id="sectitle0095">Pharmacokinetic study of compound P-3 on rats</ce:section-title>
                        <ce:para id="p0125" view="all">The pharmacokinetic property of compound P-3 was evaluated on five male Sprague-Dawley (SD) rats weighing 300 ± 10g by intragastric administration at the dosage of 100 mg/kg. The pharmacokinetic parameters were shown in <ce:cross-ref id="crosref0390" refid="tbl2">Table 2</ce:cross-ref>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor> and the pharmacokinetic curve can be seen in <ce:cross-ref id="crosref0395" refid="fig11">Fig. 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor>, which indicated that compound P-3 quickly reached its peak concentration at 0.1495 μg/mL 1 h later after oral administration. The concentration of compound P-3 declined by half 7.58 h later after peaking, which displayed a comparatively long time-span of action for compound P-3.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0100">Conclusion</ce:section-title>
                  <ce:para id="p0130" view="all">To conclude, inspired by the vital role of inflammation in tumor initiation and progression, potential anti-cancer and anti-inflammation effects of melatonin derivatives, and the merit of proper acidity of the compounds achieved by combination strategy, a series of melatonin derivatives were designed and synthesized to explore their anti-tumor effect on inflammation-dependent cancers. The results displayed the great anti-proliferation effect of these compounds especially for compound P-3 with IC<ce:inf loc="post">50</ce:inf> values on each tested cell line ranging from 7.37 to 18.62 μM. In subsequent research, favorable effects of compound P-3 on decreasing the release of pro-tumorigenic cytokines IL-6 and TNF-α in immune cells RAW 264.7, down-regulating the expression of STAT3 and inhibiting the activation of STAT3 in HCT-116 and MGC-803 cells, blocking the nuclear translocation of STAT3 in HCT-116 and MGC-803 cells to curb inflammation-induced cancer were disclosed. Additionally, another ROS-dependent mechanism of compound P-3 to induce the apoptosis of HCT-116 cells was also explored. All in all, the strategy of obstructing the progression from chronic inflammation to cancer by targeting the pivotal participators in the mutual-promotion processes between the two diseases has been proven feasible and is well worth further practicing and developing.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0105">Experiment</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0110">Chemistry</ce:section-title>
                     <ce:para id="p0135" view="all">All chemicals used were of reagent grade. Proton (<ce:sup loc="post">1</ce:sup>H) and carbon (<ce:sup loc="post">13</ce:sup>C) NMR spectra (400 or 300 MHz for <ce:sup loc="post">1</ce:sup>H NMR; 101 MHz for <ce:sup loc="post">13</ce:sup>C NMR) were recorded on a Bruker spectrometer (Bruker Company, Germany). NMR spectra used DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>, CDCl<ce:inf loc="post">3</ce:inf> or acetone-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>6</ce:italic>
                        </ce:inf> as solvent (TMS as the internal standard). Proton chemical shifts are reported relative to a residual solvent peak (CDCl<ce:inf loc="post">3</ce:inf> at 7.26 ppm, DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> at 2.50 ppm, acetone-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>6</ce:italic>
                        </ce:inf> at 2.05 ppm). Carbon chemical shifts are reported relative to a residual solvent peak (CDCl<ce:inf loc="post">3</ce:inf> at 77.00 ppm, DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> at 39.96 ppm, acetone-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>6</ce:italic>
                        </ce:inf> at 29.70 ppm). The values of the chemical shifts are expressed in ppm and the coupling constants (<ce:italic>J</ce:italic>) in hertz. The following abbreviations were used to designate multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad. High-resolution mass spectrometry (HRMS) analysis was performed using a Bruker Daltonics Apex II 47e Specification (Bruker Company, Germany).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0115">HPLC analysis</ce:section-title>
                     <ce:para id="p0140" view="all">The purity was determined by high performance liquid chromatography (HPLC). Purity of all final compounds was more than 95% (Agilent 1260 Infinity II; USA). The column was Eclipse Plus C18 (4.6 × 150 mm, 4 μm). Chromatographic conditions for all compounds: Mobile phase: 0–7 min, MeOH:H<ce:inf loc="post">2</ce:inf>O = 20:80; 7–16 min MeOH:H<ce:inf loc="post">2</ce:inf>O = 95:5, 16–25 min MeOH:H<ce:inf loc="post">2</ce:inf>O = 20:80; Wavelength: 254 nm; Column temperature: 25 °C; Flow rate of 0.5 mL/min.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0120">General procedure for the preparation of compounds</ce:section-title>
                     <ce:para id="p0145" view="all">
                        <ce:display>
                           <ce:figure id="undfig2">
                              <ce:alt-text id="alttext0015" role="short">Image 2</ce:alt-text>
                              <ce:link locator="fx2" xlink:href="pii:S0223523420309995/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                           </ce:figure>
                        </ce:display>
                     </ce:para>
                     <ce:para id="p0150" view="all">A mixture of ortho-iodo benzoic acid (1.0 mmol, 1.0 eq), amine (1.2 mmol, 1.2 eq), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.0 mmol, 1.0 eq), copper powder (10 mol%) and DMF (2.0 mL) were stirred at 100 °C in the schlenk tube for 12 h under argon condition, and then cooled to room temperature. The dark green solid was diluted with water and acidified with HCl until pH of 2 was reached. A large amount of black solid was precipitated. The suspension was filtered, washed with an excess of water to remove amine and then filter cake was dissolved in dichloromethane. The solvent was removed by rotary evaporation under reduced pressure and dried over sodium sulfate and concentrated. The crude compounds, o-aminobenzoic acid derivatives, were obtained without further purification. Then o-aminobenzoic acid derivatives (1 mmol, 1.0 eq), tryptamine (1 mmol, 1.0 eq), EDCI·HCl (1.2 mmol, 1.2 eq), HOBT (1.2 mmol, 1.2 eq) were dissolved in dichloromethane (5 mL) at 0 °C, then Et<ce:inf loc="post">3</ce:inf>N (2.5 eq) was added. The reaction system was then increased to room temperature and stirred for 8 h. After completion of the reaction detected by TLC, the reaction liquid was removed by rotary evaporation under reduced pressure. Then the resulting residue was purified by silica gel flash column chromatography to afford the desired product as a solid and the total yield in two steps was 50–90%.</ce:para>
                     <ce:section id="sec4.3.1" view="all">
                        <ce:label>4.3.1</ce:label>
                        <ce:section-title id="sectitle0125">
                           <ce:italic>N-(2-(5-methoxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(phenylamino)benzamide</ce:italic> 
                           <ce:bold>(P-1)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0155" view="all">White solid (75% yield), mp 121–122 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.67 (s, 1H, C<ce:italic>NH</ce:italic>C), 9.77 (s, 1H, C<ce:italic>NH</ce:italic>CH), 8.69 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.63 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, arom.), 7.37–7.26 (m, 4H, arom.), 7.23 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H, arom.), 7.16 (s, 1H, NH<ce:italic>CH</ce:italic>C), 7.14 (s, 2H, arom.), 7.07 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H, arom.), 6.97 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, arom.), 6.85–6.77 (m, 1H, arom.), 6.71 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H, arom.), 3.73 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>), 3.53 (dd, <ce:italic>J</ce:italic> = 13.2, 6.8 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.92 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.21 (NH<ce:italic>C</ce:italic>O), 153.44 (arom.), 144.71 (arom.), 141.99 (arom.), 132.25 (arom.), 131.83 (arom.), 129.87 (arom.), 129.25 (arom.), 128.07 (arom.), 123.77 (arom.), 122.17 (arom.), 119.83 (arom.), 119.36 (arom.), 118.49 (arom.), 115.36 (arom.), 112.48 (arom.), 112.15 (arom.), 111.55 (arom.), 100.59 (arom.), 55.71 (CH<ce:inf loc="post">3</ce:inf>N), 40.51(CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.49 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> 386.1863; found 386.1867.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.2" view="all">
                        <ce:label>4.3.2</ce:label>
                        <ce:section-title id="sectitle0130">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(methyl(phenyl)amino)benzamide</ce:italic> 
                           <ce:bold>(P-2)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0160" view="all">White solid (50% yield), mp 103–105 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.33–8.25 (m, 1H, C<ce:italic>NH</ce:italic>CH), 8.21 (dd, <ce:italic>J</ce:italic> = 7.8, 1.7 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.63 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, arom.), 7.54 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, arom.), 7.37 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H, arom.), 7.33–7.24 (m, 2H, arom.), 7.23–7.13 (m, 3H, arom., NH<ce:italic>CH</ce:italic>C), 7.09–7.04 (m, 1H, arom.), 6.98 (dd, <ce:italic>J</ce:italic> = 7.8, 1.1 Hz, 1H, arom.), 6.91 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, arom.), 6.63–6.50 (m, 3H, arom.), 3.77 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.92 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.69 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 165.71 (NH<ce:italic>C</ce:italic>O), 149.12 (arom.), 148.13 (arom.), 136.45 (arom.), 132.44 (arom.), 131.45 (arom.), 130.94 (arom.), 128.95 (arom.), 127.72 (arom.), 126.95 (arom.), 126.53 (arom.), 122.37 (arom.), 122.01 (arom.), 119.74 (arom.), 119.27 (arom.), 118.74 (arom.), 116.27 (arom.), 112.44 (arom.), 111.23 (arom.), 40.24 (CH<ce:inf loc="post">3</ce:inf>N), 39.32 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 24.87 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">3</ce:inf>O 370.1914; found 370.1910.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.3" view="all">
                        <ce:label>4.3.3</ce:label>
                        <ce:section-title id="sectitle0135">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((3-chloro-2-methylphenyl)amino)benzamide</ce:italic> 
                           <ce:bold>(P-3)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0165" view="all">White solid (90% yield), mp 164–165 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.84 (s, 1H, C<ce:italic>NH</ce:italic>CH), 9.79 (s, 1H, C<ce:italic>NH</ce:italic>C), 8.75 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.66 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.58 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.37–7.30 (m, 2H, arom.), 7.29 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 1H, arom.), 7.21 (s, 1H, arom.), 7.19 (s, 1H, NH<ce:italic>CH</ce:italic>C), 7.15 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, arom.), 7.07 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 7.04–6.95 (m, 2H, arom.), 6.83 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 3.56 (dd, <ce:italic>J</ce:italic> = 13.3, 7.0 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.98 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.29 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.27 (NH<ce:italic>C</ce:italic>O), 145.15 (arom.), 142.00 (arom.), 136.69 (arom.), 134.80 (arom.), 132.29 (arom.), 129.15 (arom.), 127.92 (arom.), 127.82 (arom.), 127.73 (arom.), 123.58 (arom.), 123.09 (arom.), 121.36 (arom.), 119.28 (arom.), 118.97 (arom.), 118.71 (arom.), 118.67 (arom.), 118.48 (arom.), 115.32 (arom.), 112.28 (arom.), 111.82 (arom.), 40.52 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.42 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 14.99 (CH<ce:inf loc="post">3</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + Na]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">22</ce:inf>ClNaN<ce:inf loc="post">3</ce:inf>O 426.1524; found 426.1363.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.4" view="all">
                        <ce:label>4.3.4</ce:label>
                        <ce:section-title id="sectitle0140">
                           <ce:italic>2-((3-chloro-2-methylphenyl)amino)-N-(2-(5-methoxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-ben-zamide</ce:italic> 
                           <ce:bold>(P-4)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0170" view="all">White solid (85% yield), mp 177–178 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.65 (s, 1H, C<ce:italic>NH</ce:italic>CH), 9.80 (s, 1H, C<ce:italic>NH</ce:italic>C), 8.72 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.65 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, arom.), 7.31 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 7.25 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, arom.), 7.21 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H, arom.), 7.18 (s, 1H, NH<ce:italic>CH</ce:italic>C), 7.13 (dd, <ce:italic>J</ce:italic> = 9.4, 4.6 Hz, 2H, arom.), 7.07 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H, arom.), 7.01 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, arom.), 6.82 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, arom.), 6.70 (dd, <ce:italic>J</ce:italic> = 8.7, 2.1 Hz, 1H, arom.), 3.73 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>), 3.53 (dd, <ce:italic>J</ce:italic> = 13.6, 6.8 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.92 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.27 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.23 (NH<ce:italic>C</ce:italic>O), 153.40 (arom.), 145.14 (arom.), 141.97 (arom.), 134.76 (arom.), 132.30 (arom.), 131.79 (arom.), 129.13 (arom.), 128.03 (arom.), 127.82 (arom.), 123.73 (arom.), 123.54 (arom.), 119.21 (arom.), 118.86 (arom.), 118.47 (arom.), 115.27 (arom.), 112.42 (arom.), 112.08 (arom.), 111.52 (arom.), 100.56 (arom.), 55.67 (OCH<ce:inf loc="post">3</ce:inf>), 40.45 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.44 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 14.92 (CH<ce:inf loc="post">3</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> 434.1630; found 434.1627.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.5" view="all">
                        <ce:label>4.3.5</ce:label>
                        <ce:section-title id="sectitle0145">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(methylamino)benzamide</ce:italic> 
                           <ce:bold>(P-5)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0175" view="all">White solid (75% yield), mp 114–115 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.83 (s, 1H, C<ce:italic>NH</ce:italic>CH), 8.43 (t, <ce:italic>J</ce:italic> = 5.3 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.70 (q, <ce:italic>J</ce:italic> = 5.1 Hz, 1H, arom.), 7.59 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.52 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.35 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, arom.), 7.28 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, arom.), 7.18 (s, 1H, NH<ce:italic>CH</ce:italic>C), 7.07 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H, arom.), 6.99 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, arom.), 6.62 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, C<ce:italic>NH</ce:italic>CH3), 6.55 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H, arom.), 3.50 (q, <ce:italic>J</ce:italic> = 7.0 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.94 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.77 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 3H, CH3). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.52 (NH<ce:italic>C</ce:italic>O), 150.54 (arom.), 136.71 (arom.), 132.69 (arom.), 128.59 (arom.), 127.74 (arom.), 123.05 (arom.), 121.38 (arom.), 118.78 (arom.), 118.68 (arom.), 115.72 (arom.), 114.33 (arom.), 112.40 (arom.), 111.84 (arom.), 110.91 (arom.), 40.32 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 29.74 (CH<ce:inf loc="post">3</ce:inf>), 25.65 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">3</ce:inf>O 294.1601; found 294.1603.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.6" view="all">
                        <ce:label>4.3.6</ce:label>
                        <ce:section-title id="sectitle0150">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(dimethylamino)benzamide</ce:italic> 
                           <ce:bold>(P-6)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0180" view="all">White solid (50% yield), mp 167–169 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.88 (s, 1H, C<ce:italic>NH</ce:italic>CH), 9.13 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.66 (dd, <ce:italic>J</ce:italic> = 7.7, 1.7 Hz, 1H, arom.), 7.60 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.39–7.33 (m, 2H, arom.), 7.23 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H, arom.), 7.13–6.96 (m, 4H, arom., NH<ce:italic>CH</ce:italic>C), 3.62 (q, <ce:italic>J</ce:italic> = 7.0 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.97 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.45 (s, 6H, N(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>3</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 167.07 (NH<ce:italic>C</ce:italic>O), 151.94 (arom.), 136.81 (arom.), 131.53 (arom.), 130.43 (arom.), 128.07 (arom.), 127.63 (arom.), 123.37 (arom.), 122.40 (arom.), 121.43 (arom.), 119.22 (arom.), 118.81 (arom.), 118.70 (arom.), 112.12 (arom.), 111.83 (arom.), 44.30 (N(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>3</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>), 40.01 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.19 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">3</ce:inf>O 308.1757; found 308.1759.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.7" view="all">
                        <ce:label>4.3.7</ce:label>
                        <ce:section-title id="sectitle0155">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((2,3-dimethylphenyl)amino)benzamide</ce:italic> 
                           <ce:bold>(P-7)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0185" view="all">White solid (85% yield), mp 143–145 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.85 (s, 1H, C<ce:italic>NH</ce:italic>CH), 9.66 (s, 1H, C<ce:italic>NH</ce:italic>C), 8.69 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.66–7.57 (m, 2H, arom.), 7.35 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.26–7.23 (m, 1H, arom.), 7.21 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H, arom.), 7.13–7.04 (m, 3H, arom., NH<ce:italic>CH</ce:italic>C), 7.01–6.96 (m, 1H, arom), 6.92 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 1H, arom), 6.87–6.83 (m, 1H, arom), 6.75–6.70 (m, 1H, arom), 3.57 (dd, <ce:italic>J</ce:italic> = 13.4, 7.1 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.99 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.27 (s, 3H, CH<ce:inf loc="post">3</ce:inf>), 2.12 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.52 (NH<ce:italic>C</ce:italic>O), 146.63 (arom.), 139.80 (arom.), 138.13 (arom.), 136.72 (arom.), 132.28 (arom.), 129.83 (arom.), 129.07 (arom.), 127.77 (arom.), 126.31 (arom.), 125.49 (arom.), 123.11 (arom.), 121.40 (arom.), 120.10 (arom.), 118.77 (arom.), 118.71 (arom.), 117.75 (arom.), 117.21 (arom.), 114.38 (arom.), 112.35 (arom.), 111.86, 40.51, 25.52, 20.78, 14.06. HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">3</ce:inf>O 384.2070; found 384.2074.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.8" view="all">
                        <ce:label>4.3.8</ce:label>
                        <ce:section-title id="sectitle0160">
                           <ce:italic>2-((2,3-dimethylphenyl)amino)-N-(2-(5-hydroxy-1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)ben-zamide</ce:italic> 
                           <ce:bold>(P-8)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0190" view="all">White solid (75% yield), mp 139–140 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.49 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H, C<ce:italic>NH</ce:italic>CH), 9.62 (s, 1H, C<ce:italic>NH</ce:italic>C), 8.64 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 1H, <ce:italic>NH</ce:italic>CO), 8.60 (s, 1H, OH), 7.64 (dd, <ce:italic>J</ce:italic> = 7.9, 1.3 Hz, 1H, arom.), 7.26–7.21 (m, 1H, arom.), 7.13 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H, NH<ce:italic>CH</ce:italic>C), 7.09 (dt, <ce:italic>J</ce:italic> = 11.0, 5.3 Hz, 3H, arom.), 6.92 (dd, <ce:italic>J</ce:italic> = 9.3, 4.5 Hz, 2H, arom.), 6.85–6.81 (m, 1H, arom.), 6.75–6.70 (m, 1H, arom.), 6.61 (dd, <ce:italic>J</ce:italic> = 8.6, 2.3 Hz, 1H, arom.), 3.52 (dd, <ce:italic>J</ce:italic> = 14.4, 6.4 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 2.92–2.85 (m, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.27 (s, 3H, CH<ce:inf loc="post">3</ce:inf>), 2.12 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.45 (NH<ce:italic>C</ce:italic>O), 150.65 (arom.), 146.67 (arom.), 139.79 (arom.), 138.12 (arom.), 132.25 (arom.), 131.29 (arom.), 129.92 (arom.), 129.03 (arom.), 128.38 (arom.), 126.29 (arom.), 125.52 (arom.), 123.52 (arom.), 120.24 (arom.), 117.71 (arom.), 117.19 (arom.), 114.33 (arom.), 112.12 (arom.), 111.76 (arom.), 111.31 (arom.), 102.74 (arom.), 40.28 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.67 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 20.73 (CH<ce:inf loc="post">3</ce:inf>), 14.04 (CH<ce:inf loc="post">3</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> 300.2020; found 400.2017.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.9" view="all">
                        <ce:label>
                           <ce:italic>4.3.9</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0165">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclopropylamino)benzamide</ce:italic> 
                           <ce:bold>(Q-1)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0195" view="all">Yellow solid (63% yield), mp 128.2–130.1 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.14 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.70 (s, 1H, <ce:italic>NH</ce:italic>CO), 7.63 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.36 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.29 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, arom.), 7.21 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 7.12 (q, <ce:italic>J</ce:italic> = 6.0, 5.6 Hz, 3H, NH<ce:italic>CH</ce:italic>C, arom.), 7.02 (s, 1H, arom.), 6.53 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 6.11 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 1H, <ce:italic>NH</ce:italic>CH(CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 3.72 (q, <ce:italic>J</ce:italic> = 6.3 Hz, 2H, NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.05 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">2</ce:inf>CH2), 2.44–2.36 (m, 1H, NH<ce:italic>CH</ce:italic>(CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 0.74 (q, <ce:italic>J</ce:italic> = 6.2 Hz, 2H, (CH<ce:italic>(CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>) 0.56–0.48 (m, 2H, (CH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.55 (NH<ce:italic>C</ce:italic>O), 150.05 (arom.), 136.26 (arom.), 132.32 (arom.), 127.08 (arom.), 126.85 (arom.), 122.12 (arom.), 121.99 (arom.), 119.38 (arom.), 118.62 (arom.), 115.15 (arom.), 115.05 (arom.), 112.97 (arom.), 112.83 (arom.), 111.17 (arom.), 39.67 (NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>) 25.13 (NH<ce:italic>CH</ce:italic>(CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>, 24.22 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 7.29 (CH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">3</ce:inf>O 320.1757; found 320.1750.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.10" view="all">
                        <ce:label>
                           <ce:italic>4.3.10</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0170">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclopentylamino)benzamide</ce:italic> 
                           <ce:bold>(Q-2)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0200" view="all">Yellow solid (68% yield), mp 152.4–152.6 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.20 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.66–7.59 (m, 2H, <ce:italic>NH</ce:italic>CO, arom.), 7.35 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.26–7.17 (m, 2H, arom, NH<ce:italic>CH</ce:italic>C), 7.15–7.07 (m, 2H, arom.), 7.00 (s, 1H, arom.), 6.69 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, arom.), 6.44 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, arom.), 6.12 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H, <ce:italic>NH</ce:italic>CH(CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 3.84–3.75 (m, 1H, NH<ce:italic>CH</ce:italic>(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 3.71 (q, <ce:italic>J</ce:italic> = 6.3 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 3.05 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, CC<ce:italic>H</ce:italic>
                           <ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.04–1.94 (m, 2H, CH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 1.78–1.68 (m, 2H, CH(CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>), 1.64–1.50 (m, 4H, CH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.84 (NH<ce:italic>C</ce:italic>O), 149.26 (arom.), 136.34 (arom.), 132.51 (arom.), 127.26 (arom.), 127.15 (arom.), 122.14 (arom.), 122.10 (arom.), 119.41 (arom.), 118.67 (arom.), 114.80 (arom.), 114.03 (arom.), 112.86 (arom.), 112.37 (arom.), 111.26 (arom.), 53.64 (NH<ce:italic>CH</ce:italic>(CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 39.72 (NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 33.34 (CH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>), 25.19 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 24.08 (CH(CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>)<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">3</ce:inf>O 348.2070; found 348.2069.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.11" view="all">
                        <ce:label>
                           <ce:italic>4.3.11</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0175">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(cyclohexylamino)benzamide</ce:italic> 
                           <ce:bold>(Q-3)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0205" view="all">Yellow solid (75% yield), mp 124.1–125.1 °C <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.29 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.66 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H, <ce:italic>NH</ce:italic>CO, arom.), 7.39 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.29–7.21 (m, 2H, arom.), 7.18–7.12 (m, 2H, arom., NH<ce:italic>CH</ce:italic>C), 7.03 (s, 1H, arom.), 6.72 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, arom.), 6.46 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H, arom.), 6.18 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H, <ce:italic>NH</ce:italic>CH(CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.76 (q, <ce:italic>J</ce:italic> = 6.4 Hz, 2H, NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.35 (s, 1H, NH<ce:italic>CH</ce:italic>(CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.09 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.10–2.00 (m, 2H, NHCH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 1.84–1.75 (m, 2H, NHCH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>), 1.70–1.59 (m, 1H, NHCH(CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>)</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>), 1.42–1.28 (m, 5H, NHCH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>)</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.72 (NH<ce:italic>C</ce:italic>O), 148.60 (arom.), 136.19 (arom.), 132.37 (arom.), 127.34 (arom.), 127.00 (arom.), 121.98 (arom.), 121.94 (arom.), 119.21 (arom.), 118.50 (arom.), 114.52 (arom.), 113.74 (arom.), 112.65 (arom.), 111.86 (arom.), 111.13 (arom.), 50.41 (NH<ce:italic>CH</ce:italic>(CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>), 39.58 (NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 32.61 (NHCH(<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)), 25.69 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 25.03 (NHCH(CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>)</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 24.59 (NHCH(CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>)<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">3</ce:inf>O 362.2227; found 362.2216.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.12" view="all">
                        <ce:label>
                           <ce:italic>4.3.12</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0180">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(benzylamino)benzamide</ce:italic> 
                           <ce:bold>(Q-4)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0210" view="all">Yellow solid (83% yield), mp 118.6–120.0 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.14–8.02 (m, 2H, C<ce:italic>NH</ce:italic>CH, <ce:italic>NH</ce:italic>CO), 7.66 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, arom.), 7.42–7.35 (m, 3H, arom.), 7.35–7.30 (m, 2H, arom.), 7.25–7.12 (m, 5H, arom., NH<ce:italic>CH</ce:italic>C), 7.09 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H, arom.), 6.59 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, arom.), 6.50 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, C<ce:italic>NH</ce:italic>CH<ce:inf loc="post">2</ce:inf>), 6.19–6.11 (m, 1H, arom.), 4.41 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 3.76 (q, <ce:italic>J</ce:italic> = 6.4 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 3.09 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.73 (NH<ce:italic>C</ce:italic>O), 149.37 (arom.), 139.16 (arom.), 136.35 (arom.), 132.61 (arom.), 128.57 (arom.), 127.19 (arom.), 127.15 (arom.), 127.04 (arom.), 126.94 (arom.), 122.29 (arom.), 122.08 (arom.), 119.55 (arom.), 118.76 (arom.), 115.36 (arom.), 114.83 (arom.), 113.03 (arom.), 112.02 (arom.), 111.26 (arom.), 47.05 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 39.74 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.27 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">3</ce:inf>O 370.1914; found 370.1905.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.13" view="all">
                        <ce:label>
                           <ce:italic>4.3.13</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0185">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((3,4-dimethoxyphenethyl)amino)benzamide</ce:italic> 
                           <ce:bold>(Q-5)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0215" view="all">Yellow solid (85% yield), mp 60.0–61.0 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.26 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.70–7.60 (m, 2H, <ce:italic>NH</ce:italic>CO, arom.), 7.35 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.26–7.23 (m, 1H, arom.), 7.22–7.17 (m, 1H, NH<ce:italic>CH</ce:italic>C), 7.16–7.08 (m, 2H, arom.), 6.97 (s, 1H, arom.), 6.83–6.76 (m, 3H, arom.), 6.67 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, arom.), 6.48 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H, C<ce:italic>NH</ce:italic>CH<ce:inf loc="post">2</ce:inf>), 6.14 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 1H, arom.), 3.87 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>), 3.82 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>), 3.71 (q, <ce:italic>J</ce:italic> = 6.3 Hz, 2H, NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.35 (q, <ce:italic>J</ce:italic> = 6.6, 6.1 Hz, 2H, NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.04 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.89 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.67 (NH<ce:italic>C</ce:italic>O), 149.27 (arom.), 148.69 (arom.), 147.36 (arom.), 136.33 (arom.), 132.60 (arom.), 132.05 (arom.), 127.24 (arom.), 127.14 (arom.), 122.10 (arom.), 120.53 (arom.), 119.37 (arom.), 118.63 (arom.), 115.20 (arom.), 114.54 (arom.), 112.77 (arom.), 111.98 (arom.), 111.43 (arom.), 111.26 (arom.), 111.14 (arom.), 55.78 (OCH<ce:inf loc="post">3</ce:inf>), 55.71 (OCH<ce:inf loc="post">3</ce:inf>), 44.90 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 39.74 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 35.16 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 25.20 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf> 444.2282; found 444.2271.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.14" view="all">
                        <ce:label>
                           <ce:italic>4.3.14</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0190">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-((4-hydroxybutyl)amino)benzamide</ce:italic> 
                           <ce:bold>(Q-6)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0220" view="all">Pale yellow solid (76% yield), mp 109.8–110.6 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, acetone-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.07 (s, 1H, C<ce:italic>NH</ce:italic>CH), 8.00 (t, <ce:italic>J</ce:italic> = 5.3 Hz, 1H, <ce:italic>NH</ce:italic>CO), 7.73 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H, arom.), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, arom.), 7.51 (dd, <ce:italic>J</ce:italic> = 7.9, 1.4 Hz, 1H, arom.), 7.41–7.35 (m, 1H, arom.), 7.27–7.20 (m, 2H, arom.), 7.13–7.07 (m, 1H, C<ce:italic>CH</ce:italic>NH), 7.05–6.99 (m, 1H, CNHCH2), 6.69 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, arom.), 6.52–6.44 (m, 1H, arom.), 3.71–3.65 (m, 3H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH, OH), 3.62 (q, <ce:italic>J</ce:italic> = 5.9 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>OH), 3.18 (q, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 3.06 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 1.78–1.62 (m, 4H, NHCH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>OH). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, acetone-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 170.98 (NH<ce:italic>C</ce:italic>O), 151.38 (arom.), 138.2 0 (arom.), 133.61 (arom.), 129.23 (arom.), 129.11 (arom.), 123.83 (arom.), 122.60 (arom.), 119.90 (arom.), 119.87 (arom.), 116.61 (arom.), 115.26 (arom.), 114.02 (arom.), 112.66 (arom.), 112.43 (arom.), 62.72 (NHCHCH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>
                           <ce:italic>OH</ce:italic>), 43.85 (NH<ce:italic>CH</ce:italic>CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>OH), 41.46 (NH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 31.84 (NHCH<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>OH), 27.03 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 26.77 (NHCHCH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>OH). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> 352.2020; found 352.2014.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.15" view="all">
                        <ce:label>
                           <ce:italic>4.3.15</ce:italic>
                        </ce:label>
                        <ce:section-title id="sectitle0195">
                           <ce:italic>N-(2-(1H-indol-</ce:italic>3-yl<ce:italic>)ethyl)-2-(4-methylphenylsulfonamido)benzamide</ce:italic> 
                           <ce:bold>(Q-7)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0225" view="all">Yellow solid (79% yield), mp 156.5–157.2 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 10.90 (s, 1H, C<ce:italic>NH</ce:italic>SO<ce:inf loc="post">2</ce:inf>), 8.12 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.70 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H, <ce:italic>NH</ce:italic>CO, arom.), 7.64 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, arom.), 7.58 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, arom.), 7.40 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, arom.), 7.34 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, arom.), 7.23 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, arom.), 7.17 (s, 1H, C<ce:italic>NH</ce:italic>CH), 7.15 (s, 1H, arom), 7.11 (dd, <ce:italic>J</ce:italic> = 7.5, 4.2 Hz, 2H, arom.), 7.04 (s, 1H, arom.), 6.93 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, arom.), 6.11 (s, 1H, arom.), 3.67 (q, <ce:italic>J</ce:italic> = 6.3 Hz, 2H, CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 3.02 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 2.31 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 168.16 (NH<ce:italic>C</ce:italic>O), 143.51 (arom.), 138.79 (arom.), 136.58 (arom.), 136.37 (arom.), 132.46 (arom.), 129.49 (arom.), 127.23 (arom.), 127.08 (arom.), 126.48 (arom.), 123.27 (arom.), 122.39 (arom.), 122.10 (arom.), 121.34 (arom.), 121.00 (arom.), 119.65 (arom.), 118.56 (arom.), 112.53 (arom.), 111.38 (arom.), 40.08 (CH<ce:inf loc="post">2</ce:inf>
                           <ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>NH), 25.03 (C<ce:italic>CH</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf>CH<ce:inf loc="post">2</ce:inf>), 21.49 (CH3). HRMS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: [M + H]<ce:sup loc="post">+</ce:sup> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S 434.1533; found 434.1537.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0200">Cells culture</ce:section-title>
                     <ce:para id="p0230" view="all">All cell lines were purchased from the American Type Culture Collection (ATCC, USA). Among them, HCT-116, SGC-7901, MGC-803, HGC-27, MCF-7 cell lines were incubated in RPMI 1640 media supplemented with 10% FBS, 100 U/mL penicillin and streptomycin at 37 °C with 5% CO<ce:inf loc="post">2</ce:inf>, while A549, HePG2, and RAW 264.7 cell lines were incubated in DMEM media supplemented with 10% FBS, 100 U/mL penicillin and streptomycin. Compounds dissolved in DMSO solution were added into cell cultural medium with the final concentrations of DMSO less than 0.1%.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0205">Proliferation evaluation</ce:section-title>
                     <ce:para id="p0235" view="all">MTT method was utilized to evaluate the anti-proliferation effect of the compounds on various kinds of cancer cell lines for primary screening. In details, cells in logarithmic phase were seeded onto 96-well plates at the density of 5 × 10<ce:sup loc="post">3</ce:sup> per well with media added in periphery wells. After adherence, compounds at gradient concentrations were added in triplicate, making the final concentrations of each compound 6.25, 12.5, 25, 50 and 100 μM. After incubation for 72 h, 10 μL of MTT solution was added to incubate with cells for 4h. Then, the MTT solution was disposed and the formed formazan crystals were fully dissolved by 150 μL of DMSO for absorbance measurement by microplate reader (Bio-Rad Laboratories, CA, USA) at 570 nm. IC<ce:inf loc="post">50</ce:inf> values were calculated with IBM SPASS statistics 25.0 software following the formula listed below. Data were given as mean ± SD from three independent experiments conducted in triplicate<ce:italic>. Inhibitory rate=1-(OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>570</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of tested well - OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>570</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of background)/(OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>570</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of control - OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>570</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of background) × 100%.</ce:italic>
                     </ce:para>
                     <ce:para id="p0240" view="all">Cell viability was monitored using a Cell Counting Kit-8 (CCK8) (Meilunbio, MA0218-5-Apr-01F) according to the manufacturer’s instructions. To be specific, MGC-803 and HCT-116 cells were seeded onto 96-well plates (5 × 10<ce:sup loc="post">3</ce:sup> cells/well). Cell viability was documented every 24 h for 2 days and detected by adding 10 μL of CCK-8 solution into each well and incubation for 1h under 5% CO<ce:inf loc="post">2</ce:inf> at 37 °C. The number of viable cells was assessed by absorbance measurement at 450 nm using a microplate reader (Bio-Rad Laboratories, CA, USA). The percentage of survival was determined using the following equation. Data were given as mean ± SD from three independent experiments conducted in triplicate. <ce:italic>Cell viability=(OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>450</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of tested well - OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>450</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of background)/(OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>450</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of control - OD</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>450</ce:italic>
                        </ce:inf> 
                        <ce:italic>value of background)×100%.</ce:italic>
                     </ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0210">EdU incorporation assay</ce:section-title>
                     <ce:para id="p0245" view="all">HCT-116 and MGC-803 cells were seeded onto 96-well plates at the density of 5 × 10<ce:sup loc="post">3</ce:sup> per well and incubated overnight. After adherence, compound P-3 at gradient concentrations was added into each well with the final concentrations of 1.25, 2.5, 5, 10 μM for HCT-116 cells and 2, 4, 8, 16 μM for MGC-803 cells. 5-FU of the highest concentration in each concentration group as a positive control and DMSO as vehicle were added. After incubation for 24 h, EdU staining assay was performed according to the manufacturer’s instructions of Cell-Light EdU Apollo 567 In Vitro Kit (Ribobio, Cat.#: C10310-1). Briefly, 100 μL of 50 μM EdU diluted in RPMI 1640 medium was added into each well and incubated for 2 h. The medium was then disposed and cells were washed with PBS twice. Afterwards, 50 μL of 4% paraformaldehyde was added to fix cells for 30 min at room temperature followed by adding 50 μL of 2 mg/mL glycine and incubating on shaker for 5 min. Next, 100 μL of 0.5% TritonX-100 solution was added into each well and washed away 10 min later with PBS before Apollo staining for 30 min in the dark (100 μL per well). Finally, 100 μL of Hoechst 33342 (Solarbio, Cat.#:B8030) was added and incubated for 30 min on shaker. The stained cells can be observed under a fluorescence microscope (Moticam Pro 282B, China).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0215">Clonogenicity assay</ce:section-title>
                     <ce:para id="p0250" view="all">HCT-116 and MGC-803 cells were seeded onto 6-well plates with each well containing 500–1000 cells. After adherence, compound P-3 at gradient concentrations was added into each well of MGC-803, making the final concentrations 2, 4, 8, 16 μM and into each well of HCT-116, making the final concentrations of 1.25, 2.5, 5, 10 μM. 5-FU of the highest concentrations in each concentration group was added as a positive control. After incubation for 6 days for MGC-803 and 9 days for HCT-116, medium was removed and cells were fixed with methanol for 15 min before stained with 1% crystal violet dye. Afterwards, excess dye was rinsed before colony-counting according to the rule that the accumulation of more than 50 cells can be counted as one colony. The relative colony ratio was determined using the following equation. The results were calculated from at least three independent experiments. <ce:italic>Relative colony ratio = (colonies of drug treated group/colonies of control group) × 100%.</ce:italic>
                     </ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0220">Cell cycle and apoptosis analysis</ce:section-title>
                     <ce:para id="p0255" view="all">HCT-116 cells and MGC-803 cells were seeded onto 6-well plates and co-cultured with compound P-3 at indicated concentrations (2.5, 5, 10, and 20 μM for 48 h). Afterwards, cells were collected by trypsinisation, washed with PBS three times and fixed with 75% ethanol at 4 °C overnight. In the following day, fixed cells were washed with PBS again, treated with Rnase, and stained with propidium iodide (PI) provided in cell cycle staining kit (MULTI SCIENCES, Cat.#: CCS012) for 30 min in the dark. The stained cells were analyzed by flow cytometry (<ce:inter-ref id="intref0020" xlink:href="http://www.baidu.com/link?url=k-nKs7ELshefFV0nwuCwPhtMxA83UQMBFnPqjnZdLpc5K19NP3b_RIjfYBT-AJIS7XTLFE5mA4NXM6cdT1BbK8VJJsRA-1jDpSPGckY2-8q" xlink:type="simple">BD LSRFortessa</ce:inter-ref> USA) within 1 h. The cell debris were gated out and at least 20,000 cells in each sample were analyzed to determine the distribution of fixed cells in each stage of cell cycle (G<ce:inf loc="post">0</ce:inf>/G<ce:inf loc="post">1</ce:inf>, S, and G<ce:inf loc="post">2</ce:inf>/M phases) with modfitLT software. The apoptosis analysis was performed according to the manufacturer’s instructions of apoptosis detection kit (Solarbio, Cat.#: CA1050). HCT-116 and MGC-803 cells were seeded onto 6-well plates and co-cultured with compound P-3 at indicated concentrations (2.5, 5, 10, 20 μM) for 48 h. Afterwards, cells were collected by trypsinisation and washed by PBS three times. Then, cells were resuspended in 1X binding buffer with 5 μl of FITC Annexin-V and 10 μL PI added into cell suspension. After incubation for 15 min in the dark, another 400 μL of 1X binding buffer was added into each sample. The stained cells were analyzed by flow cytometry (<ce:inter-ref id="intref0025" xlink:href="http://www.baidu.com/link?url=k-nKs7ELshefFV0nwuCwPhtMxA83UQMBFnPqjnZdLpc5K19NP3b_RIjfYBT-AJIS7XTLFE5mA4NXM6cdT1BbK8VJJsRA-1jDpSPGckY2-8q" xlink:type="simple">BD LSRFortessa</ce:inter-ref> USA). The cell debris were gated out and at least 10,000 cells in each sample were analyzed. Apoptotic cells were quantified with Flowjo software. The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0225">Hoechst staining and Giemsa staining assays</ce:section-title>
                     <ce:para id="p0260" view="all">HCT-116 cells at the density of 5 × 10<ce:sup loc="post">4</ce:sup> were seeded onto 6-well plates and incubated for 24 h. After adherence, cells were treated with compound P-3 at the concentrations of 1.25, 2.5, 5, 10 μM for Hoechst staining assay or at 2.5, 5, 10, 15 μM for Giemsa staining assay. After incubation for 48, the supernatant was disposed and cells were washed with PBS twice before fixed with 4% paraformaldehyde for 15 min. Subsequently, fixed cells were stained with 10 μg/mL of Hoechst 33342 for 30 min in the dark or stained with Giemsa Staining solution (Solarbio, Cat.#: G1010) for 30 min. The redundant dye was washed away with PBS and the fluorescence or morphological changes of cells were observed under a microscopy (<ce:inter-ref id="intref0030" xlink:href="http://www.baidu.com/link?url=_d_6KCnMPBoeM1Kbk3feGAz0wGG9Eqh2jyrww1JOolTfUBdrZo88XXT3fG5okS4rVHp-g3zB5ewjrm0IQTPtXNTi3ssOSUk5qVZfqWIoA6y" xlink:type="simple">Moticam Pro 282B</ce:inter-ref>, China).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.10" view="all">
                     <ce:label>4.10</ce:label>
                     <ce:section-title id="sectitle0230">Transwell assays</ce:section-title>
                     <ce:para id="p0265" view="all">Migration and invasion of HCT-116 and MGC-803 cells were assessed using QCM™ 24-Well Colorimetric Cell Migration Assay Kit (Costar) according to the manufacturer’s instructions. Briefly, 8 × 10<ce:sup loc="post">4</ce:sup> of HCT-116 cells in 200 μL of serum-free medium were added into the upper chambers. 600 μL of 20% FBS-containing medium as a chemoattractant was added into the lower chambers. Cells were incubated with compound P-3 at different concentrations (2.5, 5, 10, 15 μM) for 36 h (HCT-116 cells) or 24 h (MGC-803 cells) respectively at standard condition (5% CO<ce:inf loc="post">2</ce:inf>, 37 °C). Non-migrating cells on the upper chambers were then scraped off with cotton swabs. Cells that migrated to the bottom of the membrane were slightly washed with PBS once and fixed with 4% paraformaldehyde, and then stained for 15 min with 1% crystal violet dye. After washing away the excess dye, the stained cells were visualized under a microscope (<ce:inter-ref id="intref0035" xlink:href="http://www.baidu.com/link?url=_d_6KCnMPBoeM1Kbk3feGAz0wGG9Eqh2jyrww1JOolTfUBdrZo88XXT3fG5okS4rVHp-g3zB5ewjrm0IQTPtXNTi3ssOSUk5qVZfqWIoA6y" xlink:type="simple">Moticam Pro 282B</ce:inter-ref>, China). For invasion assay, 50 μL of diluted matrigel (1:8) was pre-coated onto the polycarbonate membrane and incubated at 37 °C, 5% CO<ce:inf loc="post">2</ce:inf> for 4 h. After solidification, the supernatant was disposed before 70 μL of serum-free medium was added into each well and incubated at standard condition for 30 min to hydrate the matrigel. Next, the supernatant was disposed again and the cells at the density of 16 × 10<ce:sup loc="post">4</ce:sup> was added into 200 μL of serum and anti-body-free medium in the upper chambers and treated with compound P-3 at different concentrations (2.5, 5, 10, 15 μM). The following steps were the same to the migration assay. To minimize the bias, at least three randomly selected fields were quantified, and the average numbers of the cells were calculated. The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.11" view="all">
                     <ce:label>4.11</ce:label>
                     <ce:section-title id="sectitle0235">Western blot analysis</ce:section-title>
                     <ce:para id="p0270" view="all">Cells in a 6-well pate were lysed using 100 μL of RIPA buffer (Solarbio, Cat.#: R0010, China) supplemented with Protease and phosphatase inhibitor cocktail (50 × , Beyotime, Cat.#: P-1045, China) after treated with P-3 for 48 h. The protein concentration in lysates was measured using a BCA Protein Assay Kit (Solarbio, Cat.#: PC0020). Next, 30–60 μg of proteins were resolved and mixed with 4 × loading buffer (Solarbio, Cat.#: P1016), electrophoresed in a 8%–12% SDS-PAGE for separation, and transferred to polyvinylidene difluoride (PVDF) membranes of 0.45 μm (Millipore Corporation, USA). The membranes were then blocked with 5% non-fat milk in Tris Buffered Saline Tween (TBST) for 2 h at room temperature on shaker and then incubated with diluted (1:500–1:1000) β-actin antibody (Affinity, Bioscience, USA, Cat.#: AF7018), STAT3 antibody (Affinity, Bioscience, USA, Cat.#: AF6294), p-STAT3 antibody (Affinity, Bioscience, USA, Cat.#: AF3293), Bcl-2 antibody (Affinity, Bioscience, USA, Cat.#: AF6139), Bax antibody (Affinity, Bioscience, USA, Cat.#: AF0120), Cyto-c antibody (Affinity, Bioscience, USA, Cat.#:BF0714) and Cleaved-caspase-3 antibody (Affinity, Bioscience, USA, Cat.#: DF6879) at 4 °C overnight. Then, uncombined primary antibodies were washed away with TBST before the bands were incubated with goat anti-rabbit IgG H + L (Affinity, Bioscience, USA, Cat.#: HRP-S0001) or goat anti-mouse IgG H + L (Affinity, Bioscience, USA, Cat.#: HRP-S0002) as secondary antibody at room temperature on shaker for 2 h. Protein blots were visualized by Tanon imaging system (Tanon Science & Technology Co., Ltd, China) after applying with ECL reagent (Millpore, Billerica, MA) and the gray level of each protein bands was detected with ImageJ software. The relative concentrations of each protein were presented as the relative signal intensity of loading control β-actin. The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.12" view="all">
                     <ce:label>4.12</ce:label>
                     <ce:section-title id="sectitle0240">ROS generation determination</ce:section-title>
                     <ce:para id="p0275" view="all">HCT-116 cells were seeded onto 6-well plates at the density of 1 × 10<ce:sup loc="post">5</ce:sup>/mL and incubated at standard condition. After adherence, cells were exposed to compound P-3 at the concentrations of 2, 4, 8,16 μM for 36 h. Subsequently, 1 μg/mL of DCFH-DA was added into each well and incubated with cells at 37 °C for 30 min in the dark. Afterwards, excess dye was washed away with PBS. ROS production in cells of each group can be visualized by green fluorescence and compared after being photographed under a fluorescence microscope (<ce:inter-ref id="intref0040" xlink:href="http://www.baidu.com/link?url=_d_6KCnMPBoeM1Kbk3feGAz0wGG9Eqh2jyrww1JOolTfUBdrZo88XXT3fG5okS4rVHp-g3zB5ewjrm0IQTPtXNTi3ssOSUk5qVZfqWIoA6y" xlink:type="simple">Moticam Pro 282B</ce:inter-ref>, China). To minimize the bias, at least three randomly selected fields were photographed. The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.13" view="all">
                     <ce:label>4.13</ce:label>
                     <ce:section-title id="sectitle0245">Nuclear translocation assay of STAT3</ce:section-title>
                     <ce:para id="p0280" view="all">MGC-803 cells grown overnight on confocal glass slides were treated with compound P-3 of 10 μM in drug-treated group or equal volume of DMSO in control group for 3 h. Then, cells were slightly rinsed with PBS and fixed with 50 μL of pre-cooled 4% paraformaldehyde for 15 min. Afterwards, sealant (1% BSA and 0.3% Triton x-100 diluted in PBS) was added and incubated with cells for 1 h at room temperature. After being washed three times with PBS, cells were stained with primary STAT3 antibody (Affinity, Bioscience, USA, Lot. AF6294) diluted in sealant at the rate of 1:100 overnight at 4 °C, followed by being incubated with <ce:inter-ref id="intref0045" xlink:href="http://www.baidu.com/link?url=bgNHD0mPWVSjR3IN29CW4zRqvvyxCcR5NMHNiUvc_aVB1f5yxZ0YU6vT64q7o4byaurx-MpSva3R3AHivck0xnfP4H_itkHxYHzEBJGdEPy" xlink:type="simple">Alexa Fluor&reg; 488 Goat Anti-Rabbit (IgG) secondary antibody</ce:inter-ref>(Invitrogen, Thermo Fisher Scientific,USA, Cat.#: A11011) diluted in sealant at the rate of 1:200 for 2 h in the dark at 37 °C. Then, cells were washed with PBS five times and incubated with 2 μg/mL of DAPI diluted in PBS for 15 min and washed with PBS twice. Images were captured with a confocal laser microscope (Zeiss LSM700，Switzerland). The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.14" view="all">
                     <ce:label>
                        <ce:italic>4.14</ce:italic>
                     </ce:label>
                     <ce:section-title id="sectitle0250">
                        <ce:italic>ELISA of IL-6 and</ce:italic> TNF-α</ce:section-title>
                     <ce:para id="p0285" view="all">RAW 264.7 cells in 6-well plates were stimulated with 2 μg/mL of LPS (Solarbio, Lot.L8880, China) except for vehicle group. Simultaneously, compound P-3 at different concentrations (5, 10, 15, 20 μM) was added into the drug-treated group. In the model group, equal volume of DMSO were added. After 24 h, cell supernatant was collected and centrifuged to dispose cell debris. Then, ELISA were performed according to the manufacturer’s instructions of ELISA kits (TNF-α: Elabscience, E-EL-M0049c; IL-6: Elabscience, E-EL-M0044c). The optical values were detected by micro reader (Bio-Rad Laboratories, CA, USA) at the wavelength of 450 nm. The concentrations of IL-6 and TNF-α were determined by comparing the optical density value of each sample to the standard curves using ELISACalc. The results were calculated from at least three independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.15" view="all">
                     <ce:label>4.15</ce:label>
                     <ce:section-title id="sectitle0255">Docking assay</ce:section-title>
                     <ce:para id="p0290" view="all">Molecular docking study of compound P-3 with the SH2 domain of STAT3 was executed using Schrodinger software package. Firstly, the X-ray crystal structure of STAT3 was obtained from Protein Data Bank (PDB code: <ce:inter-ref id="intref0050" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) and prepared with the Protein Preparation Wizard model. The specific process was including the removal of one monomer, the addition of missing hydrogen atoms, optimization of the assignment of bond order and the protonation states, and a restrained minimization using the OPLS-2005 force field. After preparing the ligands, the receptor grid was generated at the centroid of selected residues (LYS591, ARG595) and the grid box size was set to 20 Å. Finally, molecular docking was carried out using the standard precision (SP) with the default settings and the corresponding data was analysis.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.16" view="all">
                     <ce:label>4.16</ce:label>
                     <ce:section-title id="sectitle0260">Acute toxicity study</ce:section-title>
                     <ce:para id="p0295" view="all">All studies involving animals were performed according to Animal Research: Reporting of <ce:italic>In Vivo</ce:italic> Experiment (ARRIVE) guidelines, and also had been approved by the Institute Ethics Committee of Lanzhou University, Gansu, China. Acute toxicity studies were carried out according to OECD Test Guidelines. To be specific, three female and three male Kunming mice weighing from 19 to 22 mg at the age of 8 weeks were purchased from the GLP laboratory of Lanzhou University. Compound P-3 was firstly dissolved in DMSO supplemented with a few drops of polyoxyethylated castor oil and polyethylene glycol as hydrotropes before adding normal saline to dilute the DMSO to make sure the concentration of DMSO less than 5%. Each mouse was treated with about 1 mL of diluted compound P-3 at the dosage of 1000 mg/kg by intragastric administration followed by 14-days close observation in terms of survival rate, feeding behavior, activity, hairs, feces and other vital signs.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.17" view="all">
                     <ce:label>4.17</ce:label>
                     <ce:section-title id="sectitle0265">Pharmacokinetics study</ce:section-title>
                     <ce:para id="p0300" view="all">Six SD rats purchased from the GLP laboratory of Lanzhou University were kept on an experimental animal room for one week for acclimatization. Afterwards, compound P-3 at 100 mg/kg diluted using the same method as mentioned above was given to five of the SD rats by intragastric administration after one-night abrosia, while the last SD rat was executed before collecting vehicle blood as much as possible to prepare compound P-3 containing serum of different concentrations for depicting standard curve. Afterwards, blood samples were taken from the five rats from hearts at the time points of 15min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, and 24h after administration. Next, serum was separated from the blood samples taken from the tested rats and the vehicle rat by centrifugation (2500 rpm, 6 min, 4 °C), diluted with methanol of twice the volume of the serum sample and filtrated with microfiltration membrane of 0.22 μm before being analyzed by liquid chromatography and mass spectrometry (LC-MS). The chromatographic column was Eclipse plus C18 (4.6 × 150 mm, 4 μm) with the mobile phase consisting of water (0.1% formic acid) and methanol. A gradient program was used for the HPLC separation at 0.5 mL/min. Chromatographic conditions: Mobile phase: 0–7 min, MeOH:H<ce:inf loc="post">2</ce:inf>O = 20:80; 7–16 min, MeOH:H<ce:inf loc="post">2</ce:inf>O = 95:5, 16–25 min, MeOH:H<ce:inf loc="post">2</ce:inf>O = 20:80; Wavelength: 254 nm; Column temperature: 25 °C. The column eluent was directly introduced into ES-API (Agilent InfinityLab LC/MSD; USA). The concentrations of compound P-3 in each tested sample were firstly calculated by comparing the responded signals to the standard curve and then the pharmacokinetic curve was depicted using Graphpad Prism 8.4.0. Subsequently, Pksolver2.0 was used to calculate the pharmacokinetic parameters. The results were calculated from the means of five independent experiments.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.18" view="all">
                     <ce:label>4.18</ce:label>
                     <ce:section-title id="sectitle0270">Statistical analysis</ce:section-title>
                     <ce:para id="p0305" view="all">All results were given as the mean ± SD; significance between the groups was determined by analysis of variance (ANOVA), followed by Fisher’s PLSD procedure for post hoc comparison, to verify the significance between two means. P values of less than 0.05 were considered significant. The data were analyzed by SPSS software.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0275">Declaration of competing interest</ce:section-title>
               <ce:para id="p0310" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0280">Acknowledgements</ce:section-title>
               <ce:para id="p0315" view="all">The financial support of this research was provided by the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100010871" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Recruitment Program of Global Experts</ce:grant-sponsor> (1000 Talents Plan) and the <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100012226" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Fundamental Research Funds for the Central Universities</ce:grant-sponsor> (<ce:grant-number refid="gs4">lzujbky-2019-ct08</ce:grant-number>), and also supported by the <ce:grant-sponsor id="gs5" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Young Scientists Fund of National Natural Science Fund</ce:grant-sponsor> (<ce:grant-number refid="gs5">81903844</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0285">Supplementary data</ce:section-title>
                  <ce:para id="p0320" view="all">Supplementary data to this article includes general information for synthesis procedure, NMR spectra for synthesized compounds, mass spectrometry for the new compounds and P-3 (with the potential for bioactivity), molecular formula strings, and cell cycle and apoptosis analysis of compound P-3 on MGC-803 cells.</ce:para>
                  <ce:para id="p0325" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0020" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420309995/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0290">Supplementary data</ce:section-title>
                  <ce:para id="p0330" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0055" xlink:href="https://doi.org/10.1016/j.ejmech.2020.113027" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.113027</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0295">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Coussens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Werb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inflammation and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>420</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>860</sb:first-page>
                              <sb:last-page>867</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nature01322</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">L. M. Coussens, Z. Werb, Inflammation and cancer, Nature 420 (2002) 860-867. https://doi.org/10.1038/nature01322.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mantovani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Allavena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Balkwill</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer-related inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>454</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>436</sb:first-page>
                              <sb:last-page>444</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nature07205</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454 (2008) 436-444. https://doi.org/10.1038/nature07205.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.</ce:given-name>
                                 <ce:surname>Vijayalekshmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>425</sb:first-page>
                              <sb:last-page>430</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-08-0149</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">B. B. Aggarwal, R. V. Vijayalekshmi, B, Sung, Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe, Clin. Canc. Res. 15 (2009) 425-430. https://doi.org/10.1158/1078-0432.CCR-08-0149.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Grivennikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Greten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immunity, inflammation, and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>883</sb:first-page>
                              <sb:last-page>899</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cell.2010.01.025</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">S. I. Grivennikov, F. R. Greten, M. Karin, Immunity, inflammation, and cancer, Cell 140 (2010) 883-899. https://doi.org/10.1016/j.cell.2010.01.025.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>deMartel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Franceschi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Infections and cancer: established associations and new hypotheses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncol. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>194</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.critrevonc.2008.07.021</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">C. deMartel, S. Franceschi, Infections and cancer: established associations and new hypotheses, Crit. Rev. Oncol. Hematol.. 70 (2009) 83-194. https://doi.org/10.1016/j.critrevonc.2008.07.021.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ogata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nishigaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>89</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccr.2009.12.008</ce:doi>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0060" xlink:href="https://www.sciencedirect.com/science/article/pii/S1535610809004309%20-%20!D.%20H.%20Broide" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S1535610809004309 - !D. H. Broide</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">H. Takahashi , H. Ogata , R. Nishigaki, https://www.sciencedirect.com/science/article/pii/S1535610809004309 - !D. H. Broide, M. Karin, Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation, Canc. Cell 17 (2010) 89-97. https://doi.org/10.1016/j.ccr.2009.12.008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Holzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Österreicher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>197</sb:first-page>
                              <sb:last-page>208</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cell.2009.12.052</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">E. J. Park, J. H. Lee , G. Y. Yu , G. He, S. R. Ali, R. G. Holzer, C. H. Osterreicher, H. Takahashi, M. Karin, Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression, Cell 140 (2010) 197-208. https://doi.org/10.1016/j.cell.2009.12.052.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Grivennikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Greten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immunity, inflammation, and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>883</sb:first-page>
                              <sb:last-page>899</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cell.2010.01.025</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">S. I. Grivennikov, F. R, Greten, M. Karin, Immunity, inflammation, and cancer, Cell 140 (2010) 883-899. https://doi.org/10.1016/j.cell.2010.01.025.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Quail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Joyce</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microenvironmental regulation of tumor progression and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1423</sb:first-page>
                              <sb:last-page>1437</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nm.3394</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">D. F. Quail, J. A. Joyce, Microenvironmental regulation of tumor progression and metastasis, Nat. Med. 19 (2013) 1423-1437. https://doi.org/10.1038/nm.3394.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Atretkhany</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Drutskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Nedospasov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Grivennikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.V.</ce:given-name>
                                 <ce:surname>Kuprash</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>168</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>98</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.pharmthera.2016.09.011</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">K. N. Atretkhany, M. S. Drutskaya, S. A. Nedospasov, S. I. Grivennikov, D. V. Kuprash, Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment, Pharmacol. Ther. 168 (2016) 98-112 . https://doi.org/10.1016/j.pharmthera.2016.09.011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Daly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The IL-6 feed forward loop: a driver of tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Semin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>53</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.smim.2014.01.007</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Q. Chang, L. Daly, J. Bromberg, The IL-6 feed forward loop: a driver of tumorigenesis, Semin. Immunol. 26 (2014) 48-53. https://doi.org/10.1016/j.smim.2014.01.007.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer — new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrc1275</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">H. Yu , R. Jove, The STATs of cancer - new molecular targets come of age, Nat. Rev. Canc. 4 (2004) 97-105. https://doi.org/10.1038/nrc1275.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nri1995</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment, Nat. Rev. Immunol. 7 (2007) 41-51. https://doi.org/10.1038/nri1995.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Steven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Itzkowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yio</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Physiol. Gastrointest. Liver Physiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>287</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>pG7</sb:first-page>
                              <sb:last-page>G17</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1152/ajpgi.00079.2004</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">H. Steven, Itzkowitz, X. Yio, Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation, Am. J. Physiol.-Gastroint. Liver Physiol. 287 (2004) pG7-G17. https://doi.org/10.1152/ajpgi.00079.2004.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Peter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Beglinger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Helicobacter pylori and gastric cancer: the causal relationship</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Digestion</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>25</sb:first-page>
                              <sb:last-page>35</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1159/000101564</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">S. Peter, C. Beglinger, Helicobacter pylori and gastric cancer: the causal relationship, Digestion 75 (2007) 25-35. https://doi.org/10.1159/000101564.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Landskron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.F.</ce:given-name>
                                 <ce:surname>Marjorie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Thuwajit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Thuwajit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Hermoso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chronic inflammation and cytokines in the tumor microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2014</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1155/2014/149185</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Landskron G, Marjorie D L F, Thuwajit P, C. Thuwajit, M. A. Hermoso, Chronic Inflammation and Cytokines in the Tumor Microenvironment, J. Immunol. Res. 2014 (2014) 19. https://doi.org/10.1155/2014/149185.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>West</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>McCuaig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Franchini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Powrie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emerging cytokine networks in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>615</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nri3896</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">N. R. West, S. McCuaig, F. Franchini, F. Powrie, Emerging cytokine networks in colorectal cancer, Nat. Rev. Immunol. 15 (2015) 615-629. https://doi.org/10.1038/nri3896.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrc906</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">J. Darnell, Transcription factors as targets for cancer therapy. Nat. Rev. Canc. 2 (2002) 740-749. https://doi.org/10.1038/nrc906.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Reiter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The melatonin rhythm: both a clock and a calendar</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Experientia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>654</sb:first-page>
                              <sb:last-page>664</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/BF01923947</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">R. J. Reiter, The melatonin rhythm: both a clock and a calendar, Experientia (1993) 49 654-664. https://doi.org/10.1007/BF01923947.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Reiter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oxidative damage in the central nervous system: protection by melatonin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Prog. Neurobiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>359</sb:first-page>
                              <sb:last-page>384</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0301-0082(98)00052-5</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">R. J. Reiter, Oxidative damage in the central nervous system: protection by melatonin, Prog. Neurobiol. 56 (1998) 359-384. https://doi.org/10.1016/S0301-0082(98)00052-5.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Blask</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Sauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Dauchy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>113</sb:first-page>
                              <sb:last-page>132</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.2174/1568026023394407</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">D. E. Blask, L. A. Sauer, R. T. Dauchy. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy, Curr. Top. Med. Chem. 2 (2002) 113-132. https://doi.org/10.2174/1568026023394407.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.N.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Tissue Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>380</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>142</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00441-019-03148-x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Q. Y. Yu, X. W. Yu, X. H. Zhong, Y. Ma, Y. Wu, T. Bian, M. Huang, X. N. Zeng, Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma, Cell Tissue Res.. 380 (2020) 129-142. https://doi.org/10.1007/s00441-019-03148-x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Carbajo-Pescador</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ordonez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Culebras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>González-Gallego</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mauriz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MELATONIN EXERTS ANTI-ANGIOGENIC ACTIVITY VIA INHIBITION OF STAT3/HIF1 alpha/VEGF IN HEPG2 CELLS</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Surg.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1111/adj.12035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">S. Carbajo-Pescador, R. Ordonez, J. Culebras, J.Gonzalez-Gallego, J. Mauriz, MELATONIN EXERTS ANTI-ANGIOGENIC ACTIVITY VIA INHIBITION OF STAT3/HIF1 alpha/VEGF IN HEPG2 CELLS, Br. J. Surg. 100 (2013) 3. https://doi.org/10.1111/adj.12035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.X.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Q.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.X.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New role of JAK2/STAT3 signaling in endothelial cell oxidative stress injury and protective effect of melatonin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:article-number>e57941</sb:article-number>
                           <ce:doi>10.1371/journal.pone.0057941</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">W. X. Duan, Y. Yang, W. Yi, J. J. Yan, Z. X. Liang, N. Wang, Y. Li, W. S. Chen, S. Q. Yu, Z. X. Jin, D. H. Yi, New role of JAK2/STAT3 signaling in endothelial cell oxidative stress injury and protective effect of melatonin, PloS One 8 (2013) e57941. https://doi.org/10.1371/journal.pone.0057941.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.G.</ce:given-name>
                                 <ce:surname>Martín</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Egea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Reiter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Romero</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The emergence of melatonin in oncology: focus on colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2239</sb:first-page>
                              <sb:last-page>2285</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/med.21582</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">E. G. Martin, J. Egea, R. J. Reiter, A. Romero, The emergence of melatonin in oncology: focus on colorectal cancer, Med. Res. Rev. 39 (2019) 2239-2285. https://doi.org/10.1002/med.21582.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chembiochem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <ce:doi>10.1002/cbic.200900172</ce:doi>
                        </sb:host>
                        <sb:comment>1906-1906</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0155">S. Fletcher, J. Singh, X. L. Zhang, P. B. Yue, B. D. G. Page, S. Sharmeen, V. M. Shahani, W. Zhao, A. D. Schimmer, J. Turkson, P. T. Gunning, Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities, ChemBioChem, 10 (2010) 1906-1906. https://doi.org/10.1002/cbic.200900172.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>[b] A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonism of the Stat3–Stat3 protein dimer with salicylic acid based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1459</sb:first-page>
                              <sb:last-page>1470</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cmdc.201100194</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">S. Fletcher, B. D. G. Page, X. L. Zhang, P. B. Yue, Z. H. Li, S. Sharmeen, J. Singh, W. Zhao,[b] A. D. Schimmer, S. Trudel, J. Turkson, P. T. Gunning, Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules, ChemMedChem 6, (2011) 1459 - 1470. https://doi.org/10.1002/cmdc.201100194.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                              <sb:last-page>1409</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bcp.2010.01.001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">X. L. Zhang, P. B. Yue, S. Fletcher, W. Zhao, P. T. Gunning, J. Turkson, A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes, Biochem. Pharmacol. 79 (2010) 1398-1409. https://doi.org/10.1016/j.bcp.2010.01.001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.M.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>193</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112217</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2020.112217</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">X. H. Fan, J. F. Li, X. M Deng, Y. M. Lu, Y. Y. Feng, S. M. Ma, H. X. Wen, Q. Y. Zhao, W. Tan, T. Shi, Z. Wang, Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation, Eur. J. Med. Chem. 193 (2020) 112217. https://doi.org/10.1016/j.ejmech.2020.112217.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Engin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Leeper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Cater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Thistlethwaite</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tupchong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>McFarlane</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Extracellular pH distribution in human tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Hyperther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>211</sb:first-page>
                              <sb:last-page>216</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3109/02656739509022457</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">K. Engin, D. B. Leeper, J. R. Cater, A. J. Thistlethwaite, L. Tupchong, J. D. McFarlane, Extracellular pH distribution in human tumors, Int. J. Hypertherm. 11 (1995) 211-216. https://doi.org/10.3109/02656739509022457.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of organelle pH in tumor cell biology and drug resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                              <sb:last-page>38</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S1359-6446(98)01276-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">S.M. Simon, Role of organelle pH in tumor cell biology and drug resistance, Drug Discov. Today 4 (1999) 32-38. https://doi.org/10.1016/S1359-6446(98)01276-8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A concise synthesis and biological study of evodiamine and its analogues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3089</sb:first-page>
                              <sb:last-page>3092</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1039/C9CC00434C</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">J. D. Deng, S. Lei, Y. Jiang, H. H. Zhang, X. L. Hu, H. X. Wen, W. Tan, Z. Wang, A concise synthesis and biological study of evodiamine and its analogues, Chem. Commun. 55 (2019) 3089-3092. https://doi.org/10.1039/C9CC00434C.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-T.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-T.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-H.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-K.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-M.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quinolone and indole alkaloids from the fruits of Euodia rutaecarpa and their cytotoxicity against two human cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Phytochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>133</sb:first-page>
                              <sb:last-page>139</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.phytochem.2014.10.020</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">N. Zhao, Z.-L. Li, D.-H. Li, Y.-T. Sun, D.-T. Shan, J. Bai, Y.-H. Pei, Y.-K. Jing, H.-M. Hua, Quinolone and indole alkaloids from the fruits of Euodia rutaecarpa and their cytotoxicity against two human cancer cell lines, Phytochemistry 109 (2015) 133-139. https://doi.org/10.1016/j.phytochem.2014.10.020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.N.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Si</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimization of rutaecarpine as ABCA1 up-regulator for treating atherosclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>884</sb:first-page>
                              <sb:last-page>888</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ml500131a</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Y.Z. Li, T.T. Feng, P. Liu, C. Liu, X. Wang, D. S. Li, N. Li, M. H. Chen, Y. N. Xu, S.Y. Si, Optimization of rutaecarpine as ABCA1 up-regulator for treating atherosclerosis, ACS Med. Chem. Lett. 5 (2014) 884-888, https://doi.org/10.1021/ml500131a.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pandolfi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.D.</ce:given-name>
                                 <ce:surname>Acierno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bortolami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>De Vita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gallo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>De Meo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>DiSanto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Costi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Simonetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Scipione</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Searching for new agents active against Candida albicans biofilm: a series of indole derivatives, design, synthesis and biological evaluation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>165</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>93e106</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2019.01.012</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">F. Pandolfi, F. D. Acierno, M. Bortolami, D. De Vita, F. Gallo, A. De Meo, R. DiSanto, R. Costi, G. Simonetti, L. Scipione, Searching for new agents active against Candida albicans biofilm: a series of indole derivatives, design, synthesis and biological evaluation, Eur. J. Med. Chem. 165 (2019) 93e106. https://doi.org/10.1016/j.ejmech.2019.01.012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Konduri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Colon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Safe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Abbruzzese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abudayyeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Basha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdelrahim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>542</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.MCT-08-0405</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">S. Konduri, J. Colon, C. H. Baker, S. Safe, J. L. Abbruzzese, A. Abudayyeh, M. R. Basha, M. Abdelrahim, Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression, Mol. Canc. Therapeut. 8 (2009) 533-542. https://doi.org/10.1158/1535-7163.MCT-08-0405.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Colon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Basha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Madero-Visbal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Konduri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Herrera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Safe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sheikh-Hamad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abudayyeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Alvarado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdelrahim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. N. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10637-009-9331-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">J. Colon, M. R. Basha, R. Madero-Visbal, S. Konduri, C. H. Baker, L. J. Herrera, S. Safe, D. Sheikh-Hamad, A. Abudayyeh, B. Alvarado, M. Abdelrahim, Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice, Invest. N. Drugs 29 (2011) 41-51. https://doi.org/10.1007/s10637-009-9331-8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Salic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Mitchison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A chemical method for fast and sensitive detection of DNA synthesis in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2415</sb:first-page>
                              <sb:last-page>2420</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1073/pnas.0712168105</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">A. Salic, T. J. Mitchison, A chemical method for fast and sensitive detection of DNA synthesis in vivo, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2415-2420. https://doi.org/10.1073/pnas.0712168105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Friedl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wolf</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>tumor-cell invasion and migration: diversity and escape mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>362</sb:first-page>
                              <sb:last-page>374</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrc1075</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">P. Friedl, K. Wolf, tumor-cell invasion and migration: diversity and escape mechanism, Nat. Rev. Canc. 3 (2003) 362-374. https://doi.org/10.1038/nrc1075.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2488</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/sj.onc.1203527</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">T. Bowman, R. Garcia, J. Turkson, R.Jove, STATs in oncogenesis, Oncogene 19 (2000) 2474-2488. https://doi.org/10.1038/sj.onc.1203527.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Daly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The IL-6 feed forward loop: a driver of tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Semin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>53</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.smim.2014.01.007</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Q. Chang, L. Daly, J. Bromberg, The IL-6 feed forward loop: a driver of tumorigenesis, Semin. Immunol. 26 (2014) 48-53. https://doi.org/10.1016/j.smim.2014.01.007.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Schumacker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reactive oxygen species in cancer cells: live by the sword, die by the sword</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cells (Cold Spring Harbor)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>241</sb:first-page>
                              <sb:last-page>252</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccr.2006.08.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">P. T. Schumacker, Reactive oxygen species in cancer cells: live by the sword, die by the sword, Cancer Cells (Cold Spring Harbor) 10 (2006) 241-252. https://doi.org/10.1016/j.ccr.2006.08.015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Reed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Double identity for proteins of the Bcl-2 family</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>773</sb:first-page>
                              <sb:last-page>776</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/42867</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">J. C. Reed, Double identity for proteins of the Bcl-2 family, Nature, 387 (1997) 773-776. https://doi.org/10.1038/42867.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>